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I. Introductory summary 
 
“There is probably no decline in structure and function more dramatic than the decline in lean body 
mass or muscle mass over the decades of life” Irwin H. Rosenberg [1] 
 
1. General introduction 
 
Worldwide, declined fertility and increased survival to older age* are leading to the rapid 
ageing of populations [2]. Most people aspire to live a long and healthy life. In 2015, the 
World Health Organization (WHO) proposed a new vision for healthy ageing. Rather than 
a disease-free concept, the updated concept of healthy ageing centers on the notion of 
functional ability: the combination of one’s intrinsic capacity (all physical and mental 
capacities), the environment, and the interaction between them [3]. The 2015 World report 
on ageing and health acknowledges that key lifestyle factors such as diet and physical 
activity may strongly influence intrinsic capacity in older age. Their impact on intrinsic 
capacity may be essential to strategies aimed at preventing or slowing declines in 
functional ability, including conditions such as frailty [3]. 
 
1.1. Sarcopenia and age-related muscle changes 
 
Sarcopenia, the progressive loss of muscle mass and function that occurs with age [4], is a 
core component of frailty [5]. Sarcopenia is a public health challenge due to the associated 
higher risk of falls, functional decline, frailty, and mortality [6]. It was first described in 
1989 by Rosenberg as an age-related decline in lean body mass that affects mobility, 
nutritional status, and independence [1]. Subsequent definitions have included measures 
of muscle function, such as muscle strength or physical performance, because muscle 
function was consistently shown to be a stronger predictor of clinical outcomes than 
muscle mass alone [7]. Present in an estimated 1-29% of community-dwelling older adults 
[8], sarcopenia is best understood as a geriatric syndrome [9] and has since 2016 an own 
ICD-10-CM† code (M62.84) [10].  
Muscle mass and muscle strength peak in young adulthood. Beginning around age 50, 
both start decreasing gradually, with a faster decline in muscle strength (Figure 1) [4]. 
Resulting predominantly from the reduction in size and number of type II muscle 
myofibers [11], loss of skeletal muscle might be perceived as a normal component of the 
ageing process. However, varying degrees of muscle mass and strength decline across the 
population [12,13] point to modifiable behavioral factors such as diet and lifestyle as 
important influencers of muscle changes [14], suggesting that these factors may play a role 
in both the prevention and treatment of sarcopenia. 
                                                
* Often defined for research purposes as 65 years and beyond. 
† ICD-10-CM: International Classification of Diseases, Tenth Revision, Clinical Modification. 
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Figure 1. Percentage loss of muscle mass and strength with age in men [4]. Reproduced 
with permission from RightsLink®/Elsevier, obtained on 24 July 2019 
 
1.2. Nutrition and ageing 
 
A consistent finding from epidemiological studies is that poor diet is common in older 
adults [15]. Food and energy intakes decline with age [16], for a variety of reasons that 
range from physiological (decreased energy needs, appetite loss, poor dentition), 
psychological (depression, cognitive decline) to socioeconomic factors (loneliness, 
economic hardship) [17]. Moreover, abilities to absorb and utilize specific micronutrients 
become less efficient with age (e.g., vitamin B12 [18], vitamin D [19]). 
Compromised nutrient intake and assimilation put older adults at risk of malnutrition* 
[20]. Estimates of the prevalence of malnutrition vary across definitions and subgroups 
studied but are consistently higher with increasing level of dependency. In a pooled 
analysis of data from 12 countries, 38% of older adults living in the community were 
malnourished or at risk for malnutrition, compared to 92% in rehabilitation settings [21]. 
Apart from general malnutrition, older adults are at risk of specific micronutrient 
deficiencies [15]. For example in Germany, the nationwide DEGS1 survey† uncovered a 
high prevalence of low vitamin D status, defined by serum 25-hydroxyvitamin D (25OHD) 
levels <50 nmol/L, in older women (69.9%) and men (62.6%) aged 65 to 79 [22], signaling a 
serious public health concern. 
                                                
* The 2017 ESPEN (The European Society of Clinical Nutrition and Metabolism) terminologies for clinical 
nutrition define malnutrition/undernutrition as “a state resulting from lack of intake or uptake of nutrition that 
leads to altered body composition (decreased fat free mass) and body cell mass leading to diminished physical 
and mental function and impaired clinical outcome from disease”. Overnutrition (overweight and obesity) and 
micronutrient abnormalities (deficiency or excess) represent other separate concepts [20]. This thesis focuses on 
nutrition-related disorders associated with a negative nutrient balance, i.e. malnutrition/undernutrition and 
micronutrient deficiencies. 
† DEGS1 survey: German Health Interview and Examination Survey for Adults 
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1.3. Associations between nutrition, muscle health, and sarcopenia 
 
The negative health consequences of malnutrition are well known. Earlier studies have 
focused on malnutrition in older adults in terms of clinical outcomes, such as morbidity 
and mortality [23,24]. More recently, the association of malnutrition with functional 
decline has become more evident. Declining food and energy intakes contribute to weight 
loss, with implications for muscle mass and function [25,26]. Thus, malnutrition has 
emerged as a potential important risk factor in the development of sarcopenia. However, 
much of the research exploring the effects of individual nutrients on sarcopenia and 
related muscle components is relatively young, as highlighted by Robinson et al. [14].  
The nutrient that has received increased research attention in relation to muscle health and 
sarcopenia is vitamin D. Despite several reasons to consider how vitamin D may influence 
skeletal muscle [27], individual observational studies examining the associations of 
vitamin D levels with changes in muscle mass and function have yielded inconsistent 
results [28-33]. Moreover, very few prospective studies have investigated vitamin D status 
in relation to the incidence of sarcopenia defined by both muscle mass and muscle 
function as requested by actual definitions of sarcopenia [28,34].  
 
Issues related to poor nutritional status are not impossible to overcome. Routine screening 
of nutritional status and early diagnosis of malnutrition are essential. However, this seems 
not to be prioritized in geriatric health care [35]. If we can understand which nutritional 
factors influence the rate of decline in muscle mass and muscle function in older age, and 
the underlying mechanisms involved, we can lay the foundation for targeted strategies 
directed to prevent or delay sarcopenia. Such a foundation would allow older adults to 
maintain a higher quality of life and promote healthy ageing.  
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2. Aim of this thesis and outline 
 
In light of the growing ageing population and the high societal relevance of successful 
healthy ageing, this cumulative thesis aims to study the nutritional status of older adults 
and to clarify its associations with sarcopenia and changes in related muscle components.  
Figure 2 outlines the thematic structure of this thesis and highlights the analyzed 
relationship of the nutritional status with muscle components and sarcopenia in older 
adults. This thematic structure serves as a basis for the three publications included in this 
cumulative dissertation. 
 
 
Figure 2.  Thesis thematic structure: linkage between nutritional status, muscle health and 
sarcopenia in older adults. Each number corresponds to one of the three publications and 
indicates the respective theme and methods used.  
 
 
In the first publication, a cross-sectional study, the focus lies on studying the nutritional 
and more specifically, the micronutrient status of older adults. We estimate the prevalence 
of vitamin D, folate, vitamin B12, and iron deficiencies and describe socio-demographic, 
lifestyle, and health determinants associated with micronutrient deficiencies in older age. 
Among others, we consider the evidence that supports the importance of diets of adequate 
quantity and quality and discuss the possibility that regular and appropriately dosed 
micronutrient supplementation might aid older adults, otherwise unable to follow dietary 
guidelines, to satisfy nutritional needs. 
 
Publication 1: Prevalence and Predictors of Subclinical Micronutrient Deficiency in 
German Older Adults: Results from the Population-Based KORA-Age 
Study. Conzade, R.; Koenig, W.; Heier, M.; Schneider, A.; Grill, E.; Peters, 
A.; Thorand, B.  Nutrients 2017, 9. 
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In the second publication, we turn our attention to the public health concern of low 
vitamin D status in older adults and consider the evidence that links vitamin D deficiency 
to sarcopenia risk in older age. We describe the prospective associations of vitamin D 
status with 3-year changes in muscle mass, strength, and physical performance, and 
explore whether low baseline vitamin D levels are linked to a higher risk for developing 
incident sarcopenia, thereby considering competing risks such as losses to follow-up due 
to death. We also consider the potential mediating role of parathyroid hormone (PTH) in 
the relationship between vitamin D status and sarcopenia. 
 
Publication 2: Vitamin D in Relation to Incident Sarcopenia and Changes in Muscle 
Parameters Among Older Adults: The KORA-Age Study. Conzade, R.; 
Grill, E.; Bischoff-Ferrari, H.A.; Ferrari, U.; Horsch, A.; Koenig, W.; 
Peters, A.; Thorand, B.  Calcif Tissue Int 2019, 105. 
 
In the third publication, we look at 6-month changes in overall nutritional status among 
older outpatients with a history of falling. We describe prospective associations of changes 
in nutritional status with changes in muscle strength and physical performance over six 
months and discuss how improvement in nutritional status may influence 
muscle/functional recovery after a fall. Lastly, we put our results in the broader context of 
patient-centered or personalized care for older adults. 
 
Publication 3: Changes in Nutritional Status and Musculoskeletal Health in a Geriatric 
Post-Fall Care Plan Setting. Conzade, R.; Phu, S.; Vogrin, S.; Bani Hassan, 
E.; Sepúlveda-Loyola, W.; Thorand, B.; Duque, G. Nutrients 2019, 11. 
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3. A brief overview of methods 
 
3.1. Study design and populations 
 
For the present thesis, data were derived from two sources: the KORA-Age Augsburg 
study (KORA: Cooperative Health Research in the Region of Augsburg) in Germany, and 
a clinical study at a falls and fractures clinic (FFC) in Australia (‘Australian FFC study’).  
The KORA-Age Augsburg study, which started in 2008/2009, is a population-based study 
of 9,197 older adults aged ≥65 years.  All participants had previously been part of the 
MONICA (Monitoring of Trends and Determinants in Cardiovascular Disease)/KORA 
health surveys S1–S4, conducted between 1984 and 2001 in the region of Augsburg. Data 
were collected via self-administered questionnaires and telephone interviews. Publications 
1 and 2 of this thesis refer to an age- and sex-stratified random sample of the cohort, of 
whom 1,079 individuals took part in a baseline physical examination in 2009 (response 
53.8%). In 2012, a follow-up physical examination took place, in which 822 men and 
women from the baseline examination participated (response 76.2%) [36].  
The Australian FFC study consists of older adults aged ≥65 years who were assessed at the 
outpatient Falls and Fractures Clinic at Western Health-Sunshine Hospital in St Albans, 
Australia, after a history of falling in the previous year. Data were collected as part of 
standard care at this health service. Publication 3 of this thesis refers to a sample of 106 
outpatients who had data from attendance at baseline (between October 2016 and 
December 2018) and from attendance at follow-up six months later. 
 
3.2. Assessment of nutritional status 
 
To evaluate nutritional status, we first zoomed in into single micronutrients using serum 
nutritional biomarkers in the KORA-Age Augsburg study, and then zoomed out into 
overall nutritional status using a nutrition screening and assessment tool in the Australian 
FFC study. 
 
Micronutrient status: Nutritional biomarkers included concentrations biomarkers that 
reflect micronutrient status, namely serum 25-hydroxyvitamin D (25OHD), folate, vitamin 
B12, and iron. The selection of cut-offs to classify subclinical micronutrient deficiency was 
informed by the literature (25OHD: <50 nmol/L [37]; folate: <13.6 nmol/L [38]; vitamin B12: 
<221 pmol/L [39]; iron: men <11.6 µmol/L, women <9.0 µmol/L [40]). Compared to clinical 
deficiency, subclinical deficiency has no recognizable clinical signs and symptoms [41]. 
Concentration biomarkers were only measured at baseline. 
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Overall nutritional status: The Mini Nutritional Assessment (MNA®) is a validated 
screening and assessment tool for older adults in every healthcare setting. The MNA 
consists of 18 items capturing anthropometric measures, dietary intake, appetite, general 
health, and mobility. The final MNA score allows grading the overall nutritional status 
according to clearly defined thresholds: MNA score ≥24/30: “well-nourished”; 17≤ MNA 
score <24: “at risk of malnutrition”; MNA score <17: “malnourished” [42]. Repeated 
measurements of the MNA were available. 
 
Furthermore, we also included data on anthropometry measurements (body weight, body 
mass index (BMI)) and dietary supplement use (mode, dosage, frequency). 
 
3.3. Assessment of muscle health  
 
Muscle mass: In the KORA-Age Augsburg study, body composition was assessed using 
bioelectrical impedance analysis (BIA). The prediction equation by Janssen et al. was then 
applied to estimate skeletal muscle mass [43]. The skeletal muscle mass index (SMI) was 
calculated as skeletal muscle mass/height2. We used population-specific cut-offs that were 
previously published in KORA-Age to define low SMI: ≤8.72 kg/m2 in men and ≤6.33 
kg/m2 in women [44]. In the Australian FFC study, body composition was assessed using 
dual-energy X-ray absorptiometry (DXA), which then automatically calculated height-
adjusted appendicular lean mass*  (ALM/height2). We used cut-offs proposed by the 
European Working Group on Sarcopenia in Older People (EWGSOP) to define low 
ALM/height²: ≤7.26 kg/m2 in men and ≤5.5 kg/m2 in women [45]. BIA and DXA rely on 
different technologies and assess slightly different aspects of muscle mass [46].  
 
Muscle strength: Handgrip strength was assessed with a hydraulic handheld 
dynamometer. We applied EWGSOP cut-offs for low grip strength: <30 kg in men and <20 
kg in women [45], in the KORA-Age Augsburg study and the Australian FFC study. 
 
Physical performance: Usual gait speed was assessed with an electronic walkway on a 
4.88-m distance, using the EWGSOP cut-off of ≤0.8 m/sec to define low physical 
performance [45]. The Timed Up and Go (TUG) test measured the time taken to stand up 
from a standard chair, walk a distance of 3 m, turn, walk back to the chair and sit down. 
We defined the cut-point of ≥13.74 sec in the KORA-Age Augsburg study [47], and used a 
previously published cut-off of ≥13.5 sec in the Australian FFC study [48].  The Short 
Physical Performance Battery (SPPB), a group of measures that combines results of 
standing balance tests, gait speed and repeated chair stands tests, was also assessed in the 
Australian FFC study, and the EWGSOP cut-off of SPPB score ≤8 points was used [45].  
                                                
* Appendicular lean mass is the portion of skeletal muscle mass contained in the limbs, and represents about 
75% of total skeletal muscle mass [46]. 
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3.4. Sarcopenia definition  
 
Sarcopenia status was determined using the diagnostic algorithm proposed in 2010 by the 
EWGSOP, namely low muscle mass combined with low muscle function (low muscle 
strength or low physical performance) [45]. 
 
3.5. Statistical methods 
 
Publication 1 has a cross-sectional design, Publication 2 combines both cross-sectional and 
longitudinal analyses, and Publication 3 has a longitudinal design.  
In all three publications, data exploration and visualization techniques were performed to 
calculate descriptive statistics and generate plots using means and standard deviations for 
continuous data and median and interquartile range for data that deviated from normal 
distribution. Categorical data were described using frequencies and percentages.  
For the main analyses, multiple linear or logistic regression analyses were performed, 
depending on whether the dependent variable was continuous or categorical, respectively. 
All analyses were adjusted for relevant confounders identified in the literature or through 
directed acyclic graphs (DAGs). Statistical analyses were performed using SAS version 9.4. 
Results were considered statistically significant with a two-sided p < 0.05. 
 
3.6. Author contributions 
 
The three publications included in this thesis are published in either Nutrients or Calcified 
Tissue International, which are both international peer-reviewed scientific journals. 
Nutrients belongs to the top 20% of journals in the Category Nutrients & Dietetics 
according to Journal Citation Reports® 2018, whereas Calcified Tissue International belongs 
to the top 50% of journals in the Category Endocrinology & Metabolism.  
In all three publications, I am the first author and was significantly involved in developing 
the research questions under the supervision of my doctoral supervisor, Prof. Barbara 
Thorand (Publications 1 and 2), or my co-supervisor in Australia, Prof. Gustavo Duque 
(Publication 3). I performed all statistical analyses and interpreted the results together with 
my supervisors and the members of my Thesis Advisory Committee. Moreover, I have 
written all manuscript drafts, incorporated co-authors' comments, finalized the 
manuscripts based on reviewers' comments, and coordinated the communication between 
co-authors and editors from each journal.  
Specifically for the KORA-Age Augsburg study, I was involved in quality control of 
biomarker measurements, thereby working closely with the KORA study center in 
Augsburg and external laboratory partners. For the Australian FFC study, I wrote the 
ethics protocols for my study (Publication 3) and coordinated the ethics approval process 
under the supervision of Prof. Gustavo Duque. 
Key findings 
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4. Key findings 
 
The overall purpose of this thesis was to study the nutritional status of older adults and 
unravel its associations with sarcopenia and changes in related muscle outcomes, 
including muscle mass, muscle strength, and physical performance. Nutritional factors of 
main interest were serum biomarkers of micronutrient status and overall nutritional status 
based on the MNA score. 
 
The starting point of this research was to obtain a better understanding of the magnitude 
of poor nutritional among older adults, with a specific focus on micronutrients. In my first 
publication, we therefore estimated the prevalence of subclinical vitamin D, folate, vitamin 
B12, and iron deficiencies among 1,079 older adults aged ≥65 years from the KORA-Age 
Augsburg study, and examined associated determinants.   
We found that the prevalence of subclinical vitamin D and vitamin B12 deficiencies among 
KORA-Age individuals were high, with 52.0% and 27.3% of older adults having low 
25OHD (<50 nmol/L) and low vitamin B12 concentrations (<221 pmol/L), respectively. 
Moreover, 11.0% had low iron (men <11.6 µmol/L, women <9.0 µmol/L) and 8.7% had low 
folate levels (<13.6 nmol/L). We identified four common determinants that were associated 
with subclinical micronutrient deficiency: age 85 years and above (ORs*: from 2.0 to 2.3, 
95% CIs: from 1.2 to 4.3); physical inactivity (ORs: from 1.4 to 2.0, 95% CIs: from 1.0 to 3.4); 
frailty (ORs: from 1.6 to 4.2, 95% CIs: from 1.0 to 10.2); and no/irregular use of 
supplements containing the specific micronutrients examined (ORs: from 3.9 to 4.8, 95% 
CIs: from 1.4 to 16.1). 
 
Key finding 1: There is a high prevalence of vitamin D and vitamin B12 deficiencies 
among older adults. 
 
In view of the high prevalence of suboptimal vitamin D levels among KORA-Age older 
adults, the aim of my second publication was to clarify whether low baseline vitamin D 
levels (<50 nmol/L) were associated with 3-year changes in muscle mass, muscle strength, 
and physical performance, and ultimately, with the incidence of sarcopenia. The role of 
PTH therein was also investigated. We studied 702 older adults from the KORA-Age 
Augsburg study with data at 3-year follow-up.  
  
                                                
* OR: odds ratio; CI: confidence interval. 
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We found that baseline 25OHD levels <25 vs. ≥50 nmol/L were associated with a 0.9% (95% 
CI: 0.3, 1.6) greater annual decrease in muscle mass and a 3.1% (95% CI: 0.6, 5.5) greater 
annual increase in time for the TUG test. Vitamin D status was not associated with 
changes in grip strength or gait speed. Low baseline vitamin D levels were not associated 
with the risk for developing incident sarcopenia, but a significant association was found 
with the combined endpoint of incident sarcopenia and death (OR: 3.19, 95% CI: 1.54, 6.57 
for 25OHD <25 vs. ≥50 nmol/L). There was no evidence for a PTH-mediating effect. 
 
Key finding 2: Low vitamin D status was associated with unfavorable changes in 
muscle mass and physical performance in older adults over three 
years, but not with incident sarcopenia. 
 
Building on the findings that low vitamin D levels and more generally a poor nutritional 
status may be early risk factors for unfavorable muscle changes, we hypothesized that 
replenishing nutritional status may help to enhance muscle health in older age. In my 
third publication, we studied changes in nutritional status among 106 older outpatients 
aged ≥65 years from the Australian FFC study, who were provided with post-fall care 
plans as part of standard care. We tested whether changes in nutritional status over six 
months were associated with changes in muscle strength and physical performance.  
Over six months, the prevalence of malnutrition or risk thereof decreased from 29% to 15% 
in older outpatients from the Australian FFC study, based on an MNA score <24/30. 
Specifically, 20 individuals (19%) improved, 7 (7%) deteriorated, and 73 (69%) maintained 
their nutritional status. A 1-point increase in MNA score over six months, indicating 
improvement in nutritional status, was associated with improvement in physical 
performance based on an increase of 0.2 points (95% CI: 0.1, 0.3) in the SPPB score.  
 
Key finding 3: Improvement in overall nutritional status over six months was 
associated with improvement in physical performance among older 
adults with a history of falling. 
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5. Discussion 
 
This work confirms the importance of maintaining nutritional adequacy in older age to 
ensure sufficient supply of essential nutrients and to preserve muscle mass and muscle 
function. It also builds on previous findings in the field of sarcopenia by thoroughly 
investigating the effects of low vitamin D status on the development of incident sarcopenia 
and on changes in related muscle components.  
The findings suggest that the nutritional and more specifically the micronutrient status of 
older adults is suboptimal. The observed high prevalence of subclinical vitamin D and 
vitamin B12 deficiencies, defined by 25OHD levels <50 nmol/L and vitamin B12 levels <221 
nmol/L, is a matter of concern. Low vitamin D status appears to be an early risk factor for 
loss in muscle mass and muscle function in older adults. The hypothesized association of 
low baseline vitamin D status with the incidence of sarcopenia could not be demonstrated, 
but a significant association persisted with the combined endpoint of incident sarcopenia 
and death. A particularly interesting and promising final result of this work is that an 
improvement in overall nutritional status seems to improve muscle function such as 
physical performance among older adults with a history of falling.  
Results of the specific analyses included in this thesis have been discussed in the 
corresponding publications. This section addresses public health implications, reviews 
general methodological issues and provides recommendations for future research. 
 
5.1. Public health implications 
 
Overall, this thesis underpins the importance from a public health perspective of 
maintaining an adequate nutritional status in older age to secure a sufficient supply of 
nutrients and to preserve muscle health.  
 
5.1.1. Ensuring an adequate nutritional status for older adults 
 
The high prevalence of micronutrient deficiencies such as vitamin D and B12 observed 
among older adults from this thesis, but also from many other studies among older 
populations [39,49], highlights the immediate need to ensure that older adults are 
effectively supported to have sufficient dietary intakes and an adequate nutritional status.  
Essential supporting strategies are routine screening of nutritional status and early 
diagnosis of malnutrition, both in the community and other healthcare settings. However, 
these strategies seem not always to be prioritized. In a postal survey among German 
geriatric hospital departments, only 40% of geriatric wards reported performing a 
standardized screening for malnutrition using a validated screening tool [35]. This finding 
highlights that malnutrition may often remain undiagnosed and hence, untreated. It 
appears that in many health services across Europe, neither routine screening for 
malnutrition nor standards of treatment exist [35]. 
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However, recent aligned efforts from major global clinical nutrition societies will enhance 
the diffusion and implementation of malnutrition awareness in clinical practice. In 2018, 
the first evidence-based universal definition of malnutrition for adults in all healthcare 
settings was published by the Global Leadership Initiative on Malnutrition (GLIM) [50], 
followed in 2019 by a new ESPEN guideline for clinical nutrition and hydration, which 
offers 82 evidence-based recommendations to treat malnutrition in older adults [51].  
For vitamin D we observed the opposite trend. Vitamin D screening and prescriptions 
have dramatically increased over the past decade. According to a recent pooled analysis of 
6 countries, population-wide vitamin D screening has become commonplace, instead of 
targeted testing of subgroups at risk of low vitamin D levels, as recommended by 
authoritative bodies and professional societies [52]. Great variability in clinicians’ 
knowledge and practices related to vitamin D, compounded by inconsistent cut-offs and 
conflicting recommendations/guidelines [52] calls for more consensus among parties to 
inform better and more consistent clinical guidelines in the field of vitamin D, including 
for older adults. 
 
5.1.2. Maintaining an adequate nutritional status for preserving muscle health 
 
This thesis advocates the potential benefits of maintaining an adequate nutritional status 
such as adequate intake of vitamin D for enhancing relevant sarcopenia-related muscle 
components, such as muscle mass and muscle function.  
The reduced muscle mass and the impaired muscle function that define sarcopenia in 
older adults are associated with functional decline and physical disability [53], with 
implications for independence, mobility, and subsequent falls [54,55].  An increased risk of 
mortality has also been evidenced in individuals with sarcopenia [6]. In our analyses, low 
vitamin D levels were associated with changes in muscle mass and function, but not with 
the risk for developing sarcopenia. Nevertheless, a significant association was found with 
the combined endpoint of incident sarcopenia and death. Future well-designed 
prospective studies that consider the issue of competing risks such as mortality in older 
cohorts might be important to clarify the role of vitamin D in the management of 
sarcopenia.  
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The association found between overall improvement in nutritional status and 
improvement in physical performance in older outpatients provides a basis for 
interventional studies to evaluate nutritional models of care to preserve muscle health in 
older age. While the management of sarcopenia today focuses on resistance training [56], 
current research is also looking at the effect of exercise combined with diet. Several studies 
have demonstrated that physical activity together with nutritional supplements can 
improve muscle function [57-59]. Large-scale trials are also underway to address the 
individual or combined effects of nutritional and/or exercise interventions in healthy older 
adults (e.g. the DO-HEALTH study*), or in older adults with sarcopenia (e.g. the SPRINTT 
trial [60,61]). With the prospect of effective interventions, the assessment and identification 
of sarcopenia should be considered to prevent adverse health outcomes [62]. 
 
5.1.3. Bridging the gaps between research and clinical practice 
 
New definitions of malnutrition and sarcopenia have been released in 2018 and 2019, 
respectively [50,63]. These updated definitions present an important crossroad for the 
diagnosis and treatment of both conditions, and an opportunity to bridge gaps between 
research and clinical practice. In 2015, the WHO launched the World Report on Ageing and 
Health [3], proposing a new framework for healthy ageing (see Introduction of this thesis). 
This report was followed in 2017 by new ICOPE† guidelines by the WHO [64], which 
provide community-level interventions for health care professionals to manage declines in 
intrinsic capacity. Mobility loss and malnutrition are specifically addressed.  
Next, national public health agencies and health authorities should strengthen their efforts 
to develop and endorse adequate guidelines and campaigns to increase malnutrition and 
sarcopenia awareness in the older population. An example is the German campaign “Fit in 
later life”, which was initiated in the framework of the National Action Plan “IN FORM: 
German national initiative to promote healthy diets and physical activity” in 2008 [65]. The 
campaign seeks to improve nutritional knowledge and dietary habits, and by extension, to 
promote health in later life for all older adults. Given global population ageing and the 
burden of sarcopenia that is associated with growing life expectancies around the world, it 
is essential to use optimal nutrition in later life as one important dimension of prevention 
for sarcopenia. 
  
                                                
* http://do-health.eu/wordpress/ 
† ICOPE: Integrated Care for Older Adults 
Discussion 
19 
5.2. Methodological considerations 
 
5.2.1. Study design and populations 
 
The KORA-Age Augsburg study provides deep phenotyping of a wide range of health-
related factors with participants being followed over several years. Its prospective design 
allows to clarify the temporal sequence between exposure and outcome, but its 
observational nature does not allow to ascertain causality [66]. Since participants had to 
visit the KORA study center, a selection bias is possible which may be responsible for 
somewhat higher rates of healthier individuals. The KORA-Age Augsburg study uses a 
large, broadly representative sample of community-dwelling older adults, which increases 
the external validity of our results.  
The Australian FFC study has the advantages of providing a scientific basis for the 
development of future prospective or interventional studies, and an opportunity for 
outpatients to play an active role in their own health care. Moreover, the availability of 
repeated measurements of the nutritional exposure makes it possible to account for the 
effects of changes in nutritional status on changes in health-related outcomes. However, 
the examined study population consists of a rather small sample of older outpatients with 
a history of falling, who differ from a healthy or otherwise diseased population. Therefore, 
our findings might not be generalizable to other population subgroups.  
 
5.2.2. Quality of the methodology 
 
A common strength from both study populations relates to the careful and standardized 
evaluation of nutritional and muscle measurements by qualified medical staff. However, 
each assessment method has its own strengths and limitations.  
Blood nutritional biomarkers can be more objectively and precisely measured than dietary 
intake using food questionnaires, though they may be affected by hydration status, 
inflammation, and diurnal variations.  Concentration biomarkers do not necessarily reflect 
the amount of micronutrient intake from foods, but relate to the nutritional status of 
micronutrients after absorption, and can directly reflect deficiency at the blood level [67]. 
The use of cut-offs to determine micronutrient deficiency may be difficult [68]. Ideally, a 
cutoff accurately distinguishes individuals with optimal from those with suboptimal 
levels. However, in real-life situations, misclassification can occur. Prevalence estimates 
may be affected, with implications for preventive and therapeutic strategies [68]. 
The MNA® is the most widely used tool for nutritional screening and assessment for older 
adults in all healthcare settings due to its ease of use, feasibility, and high sensitivity. 
Structured in 18 questions grouped in five rubrics, it captures the potential multifactorial 
origin of malnutrition [69]. Changes in nutritional status upon reassessment are reflected 
by corresponding changes in MNA score [70], making the MNA useful to assess changes 
in nutritional status over six months in the Australian FFC study. 
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A broad spectrum of muscle components was used to assess sarcopenia. A common 
problem is the difficulty to measure muscle mass accurately. Bioelectrical impedance 
analysis (BIA) is inexpensive, quick, and easy to use; however, it is affected by hydration 
status, the device, and the equations used to predict muscle mass [46]. Dual-energy X-ray 
absorptiometry (DXA) is currently the most widely used method; however, it is relatively 
expensive, not portable, and can overestimate or underestimate muscle mass [46]. New 
promising techniques for the assessment of muscle mass are emerging, including one 
based on the dilution of oral D3-creatine [71]. Muscle strength and physical performance 
measures are limited by pain, including arthritis or neurological disorders.  
Of important note, the EWGSOP sarcopenia definition has been updated as EWGSOP2 in 
2019, after the conception of the three publications comprising this thesis. The EWGSOP2 
proposes a new diagnosis approach for sarcopenia, in which low muscle strength comes to 
the forefront as primary indicator of probable sarcopenia, rather than muscle mass [63]. 
These updated EWGSOP2 recommendations, which include clear cut-off points for 
measurements of variables, are expected to increase consistency of research design in the 
field of sarcopenia and facilitate early identification of sarcopenia in clinical practice [63].  
Last, but not least, we have been able to include in our analyses a wide range of relevant 
confounders, thereby minimizing confounding in examining potential causal associations 
of the nutritional and the vitamin D status with sarcopenia and muscle-related outcomes. 
However, imperfectly measured or unmeasured confounders cannot be ruled out, and this 
can result in residual confounding. 
 
5.3. Future research 
 
Overall, our findings indicate the potential benefits of healthier dietary habits leading to 
adequate micro- and macronutrient intake to preserve muscle mass and function, with 
implications for sarcopenia prevention and treatment.  
 
5.3.1. Nutritional interventions in sarcopenia 
 
Evidence gathered throughout this thesis is observational and from two high-income 
countries (Germany and Australia). Hence, further high-quality randomized controlled 
trials in more diverse populations are needed to ascertain causality and better understand 
dose and duration effects of specific nutritional interventions on relevant muscle 
outcomes. Further mechanistic studies that explain mechanistic links are also required.  
The advent of patient-centered or personalized care has increased attention to the fact that 
different settings and populations can require different management and treatment 
approaches for sarcopenia [72]. Hence, future work should also consider the role of 
tailored interventions in specific settings (e.g. in the community vs. in hospitals) and 
subgroups of the older population. Potential relevant subgroups are older adults who 
have specific phenotypic characteristics (e.g. falls), or who differ in either their usual diets 
(e.g. low protein diet) or in their nutritional status (e.g. low 25 OHD levels).  
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Moreover, nutritional research into sarcopenia needs to expand outside of protein and 
vitamin D research. Antioxidant nutrients and long-chain polyunsaturated fatty acids 
deserve research attention, as do specific foods (including dairy and nitrate-rich foods) 
and dietary patterns [14]. Promising novel nutritional interventions in sarcopenia were 
presented at the 2019 International Conference on Frailty and Sarcopenia Research 
(ICFSR), which I have attended with great interest. For example, omega-3 polyunsaturated 
fatty acid (fish oil) supplements with resistance training have shown interesting results in 
women with sarcopenia [73].   
 
5.3.2. Life-course approach to sarcopenia 
 
One novelty of the updated EWGSOP2 definition for sarcopenia is to highlight the 
potential role of sarcopenia in earlier stages of life [63]. The hypothesis is that muscle mass 
and strength achieved in later life are not only determined by the rate of skeletal muscle 
loss and the factors that influence this (e.g., diet, lifestyle) but also by the peak attained 
earlier in young adulthood (Figure 1 of this thesis). Future research into the prevention of 
sarcopenia needs to explore the potential effectiveness of nutritional interventions earlier 
in the life course [63]. 
This life-course approach to sarcopenia suggests that studies such as birth cohorts with 
longer follow-up and repeated measurements would be needed to examine associations 
between early life nutritional factors and changes in muscle outcomes over the life course. 
These follow-up studies would enable us to investigate to what extent nutritional factors 
impact later adulthood and how they affect the risk of developing sarcopenia in later life. 
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6. Conclusions 
 
To develop strategies that prevent or delay sarcopenia, a better understanding of lifestyle 
behaviors that influence age-related changes in muscle mass and function is needed.  
Findings from this thesis indicate the importance of maintaining nutritional adequacy in 
older age, to ensure sufficient supply of essential nutrients such as vitamin D, and to 
enhance muscle health. Vitamin D levels ≥50 nmol/L and an overall adequate nutritional 
status seem to be beneficial for relevant sarcopenia-related muscle components, including 
muscle mass and muscle function. Although this evidence is observational and the 
mechanisms are not fully understood, the high prevalence of subclinical vitamin D 
deficiency observed among older adults makes this a current concern.  
Optimizing nutrition and ensuring an adequate nutritional status for older adults may be 
key to preventing or delaying sarcopenia, enabling mobility and independence into older 
age. Further randomized trials are needed to assess whether the observed associations are 
causal and to determine optimal nutrient levels for muscle health. My hope is that 
upcoming nutritional treatment options will lower the burden of both malnutrition and 
sarcopenia for older adults. 
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Abstract: Subclinical micronutrient deficiency in older adults is associated with chronic age-related
diseases and adverse functional outcomes. In Germany, the older population is at risk of insufficient
micronutrient intake, but representative studies on micronutrient status in old and very old adults
are scarce. This study’s objectives were to estimate the prevalence of subclinical vitamin D, folate,
vitamin B12 and iron deficiencies among older adults, aged 65 to 93, from the KORA-Age study
in Augsburg, Germany (n = 1079), and to examine associated predictors, using multiple logistic
regression. Serum concentrations of 25-hydroxyvitamin D (25OHD), folate, vitamin B12, and
iron were analyzed. The prevalence of subclinical vitamin D and vitamin B12 deficiencies were
high, with 52.0% and 27.3% of individuals having low 25OHD (<50 nmol/L) and low vitamin B12
concentrations (<221 pmol/L), respectively. Furthermore, 11.0% had low iron (men <11.6 µmol/L,
women <9.0 µmol/L) and 8.7% had low folate levels (<13.6 nmol/L). Common predictors associated
with subclinical micronutrient deficiency included very old age, physical inactivity, frailty and
no/irregular use of supplements. Subclinical micronutrient deficiency is a public health concern
among KORA-Age participants, especially for vitamins D and B12. The predictors identified
provide further rationale for screening high-risk subgroups and developing targeted public health
interventions to tackle prevailing micronutrient inadequacies among older adults.
Keywords: subclinical micronutrient deficiency; vitamin D; folate; vitamin B12; iron; predictors;
older adults; population-based study; Germany
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1. Introduction
Deficiencies in essential vitamins, minerals and trace elements (micronutrients) affect an estimated
2 billion people, in both developing and developed countries. This ‘hidden hunger’ has negative
health impacts among vulnerable groups in the population, especially older adults [1].
Epidemiological evidence suggests that subclinical micronutrient deficiencies in older adults are
associated with chronic age-related diseases and adverse functional outcomes. Older adults with low
25-hydroxyvitamin D (25OHD) levels have a significantly higher risk for type 2 diabetes mellitus,
cardiovascular disease (CVD) and osteoporosis-related fractures [2]. Age-associated declines in muscle
mass and strength (sarcopenia), which in turn affect balance, gait, and overall independence [3], have
been linked to low 25OHD levels as well [4]. Vitamin B12 and folate are necessary for one-carbon
metabolism and DNA synthesis, and have been investigated in relation to degenerative diseases,
including CVD, cognitive dysfunction and osteoporosis [5]. Iron deficiency is the most prevalent
nutritional deficiency worldwide and its main consequence is anemia [6], which has been associated
with an increased risk of developing dementia in old age [7].
Ageing is associated with physiological changes that can impact the nutritional and more
specifically the micronutrient status of older adults. Importantly, energy requirements decrease due to
a loss of lean body mass and a reduction in physical activity, resulting in decreasing energy intakes.
At a low energy intake, older adults may be at increased risk for specific micronutrient deficiencies,
unless their diets contain micronutrient-rich foods. Moreover, older adults’ abilities to absorb and
utilize specific micronutrients become less efficient (e.g., reduced gastric acid secretion preventing the
release of vitamin B12 from foods [5]; decline in subcutaneous vitamin D synthesis capacity and lowered
renal conversion to its active form [8]). Last, but not least, the likelihood of multiple chronic diseases,
such as cardiovascular disease, type 2 diabetes mellitus and cancer, use of multiple medications and
variable diet quality, associated with appetite loss, chewing/swallowing difficulties and socioeconomic
barriers, may affect and even increase requirements for specific micronutrients [9,10]. All these factors
make it difficult to ensure an optimal micronutrient supply for the older population.
Due to the role of micronutrient status in chronic disease and health prevention, it is important to
quantify the magnitude of subclinical micronutrient deficiency and to identify subgroups at risk in the
older population. Results from the second German National Nutrition Survey (NVS II) uncovered
a high prevalence of insufficient dietary intake of vitamin D, folic acid and calcium in older adults
aged 65 years and over. Vitamins B1, B2, B12 and iron were additional critical micronutrients in older
women [11]. More recently, the national ‘German Health Interview and Examination Survey for
Adults’ (DEGS1) revealed that 69.9% of women and 62.6% of men, aged 65 to 79, had low 25OHD
<50 nmol/L [12], signaling a potentially serious public health issue. Nationally representative studies
on the statuses of other micronutrients, in old and very old adults, in Germany, are scarce.
To support health care in developing purposive prevention measures that handle micronutrient
inadequacies among older adults, factors associated with subclinical micronutrient deficiencies in
older adults have to be identified. Besides insufficient dietary intake and impaired absorption, low
micronutrient levels in older adults have been studied in relation to increasing age, female sex, poor
eating habits, low physical activity, smoking, obesity, low kidney function, presence of chronic diseases,
intake of drugs, non-use of supplements and, specifically for vitamin D, low sunlight exposure and
winter season [13–18]. Despite recent concerns about the possible high prevalence of subclinical
micronutrient deficiencies in the German older population, and apart from vitamin D [12,18], there is
a lack of data on both micronutrient status and its predictors in older adults.
In light of the growing ageing population, as well as the high societal relevance of successful
healthy ageing, this cross-sectional study aimed to provide insight into the magnitude of subclinical
micronutrient deficiency in German older adults, aged 65 and over, from the population-based KORA
(Cooperative Health Research in the Region of Augsburg)-Age study. Based on the micronutrients
identified in the NVS II as possible public health concerns in the German older population, we
selected four critical micronutrients with available nutritional biomarkers in the KORA-Age dataset.
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Specific objectives were (i) to determine the prevalence of subclinical vitamin D, folic acid, vitamin
B12 and iron deficiencies in this older population, using serum biochemical biomarkers; and (ii) to
identify predictors of subclinical micronutrient deficiency using multiple logistic regression. Possible
predictors examined included socio-demographic, lifestyle, and health factors, as well as the use of
supplements containing specific micronutrients.
2. Materials and Methods
2.1. Study Design and Participants
Data for the present analysis was obtained from the population-based KORA-Age study,
conducted in 2008/2009, which was a follow-up of all participants, aged 65 and over on
31 December 2008 (n = 9197), who took part in at least one of four cross-sectional MONICA (Monitoring
of Trends and Determinants in Cardiovascular Disease)/KORA health surveys S1–S4 conducted
between 1984 and 2001, among the inhabitants of Augsburg and surrounding counties. Details
about the general study design and participants have been described previously [19]. Briefly, a
self-administered health questionnaire was mailed to all eligible participants of the KORA-Age cohort,
i.e., those who were still alive and reachable in 2008/2009 (n = 5991). The response rate was 76.2%
(n = 4565). Moreover, 68.9% of eligible participants took part in a standardized telephone interview
(n = 4127). The present analysis refers to a sex and age-stratified random sample of n = 2005 eligible
individuals of whom n = 1079 (537 men, 542 women) participated in an extensive physical examination
in 2009 (response rate 53.8%). All examinations were performed by trained interviewers. A flowchart
of the KORA-Age 2008/2009 recruitment and retention profile is shown in Supplementary Figure S1.
2.2. Ethical Considerations
Prior to their inclusion in the study, written informed consent was obtained from all participants or
from the patient’s caregiver when the participant was unable to make an informed decision. The Ethics
Committee of the Bavarian Medical Association (Bayerische Landesärtzekammer) approved the study
protocol (date of approval: 11 November 2008, reference number: 08064).
2.3. Blood Sample Processing
Non-fasting blood samples were collected between February and November 2009 at the KORA
study center and drawn into serum gel S-Monovette tubes (Sarstedt, Nümbrecht, Germany). Blood was
gently inverted twice and rested for 30 min at room temperature until complete coagulation.
After centrifugation at 15  C for 10 min, the serum obtained was aliquoted into Nunc cryotubes
(Thermo Fisher Scientific, Waltham, MA, USA). For the analysis of iron status, serum probes were
kept at 4  C for a maximum of 6 h and directly analyzed at the central laboratory of Augsburg
Hospital. For vitamin D, folic acid and vitamin B12 status, serum probes were frozen at  80  C
at the KORA study center, transported on ice and stored at a minimum of  80  C until analysis,
in partner laboratories, between August and September 2011. Months of blood collection were
categorized according to calendar seasons: spring (February–May), summer (June–August) and
autumn (September–November).
2.4. Biochemical Analyses of Nutritional Biomarkers
Serum concentrations of 25-hydroxyvitamin D (25OHD), folate and cobalamin (vitamin B12) were
measured by an electrochemiluminescence immunoassay (ECLIA, Elecsys 2010, Roche Diagnostics
GmbH, Mannheim, Germany). The intra- and inter-assay coefficients of variations were 4.9% and
<10% for 25OHD, 7.0% and <10% for folate and 5.3% and <10% for vitamin B12. Iron levels were
measured by photometric measurements, using the chromophore Ferene® (Dimension® Iron Flex®
reagent cartridge, Dade Behring, Inc., Newark, DE, USA). The inter-assay coefficient of variation was
<10%, and the maximal permissible imprecision and inaccuracy were 4% and 6%, respectively.
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2.5. Cut-Off Points to Classify Subclinical Micronutrient Deficiency
Exact cut-off points for classifying subclinical micronutrient deficiencies remain debated.
Recently, a serum 25OHD level of  50 nmol/L was recommended as an indicator of optimal vitamin
D status by the critical review of the German Nutrition Society (DGE) for DACH countries (Germany,
Austria and Switzerland) [20] as well as the last Nordic Nutrition Recommendations (NNR 2012) [21].
Accordingly, subclinical vitamin D deficiency was defined as a serum 25OHD level of <50 nmol/L.
Subclinical folate and vitamin B12 deficiencies were defined as serum folate <13.6 nmol/L [22] and
serum vitamin B12 <221 pmol/L [23], respectively. For serum iron, cut-offs were <11.6 µmol/L for
men and <9.0 µmol/L for women [24].
2.6. Assesment of Predictors
The selection of potential predictors of subclinical micronutrient deficiencies was informed by
the literature and their availability in the KORA-Age dataset. Variables were grouped into three
categories (socio-demographic, lifestyle, health factors) plus the season of blood collection for vitamin
D. Assessment methods and categorization of variables are described in Supplementary Table S1.
Briefly, the variables—sex, age groups and family status—were collected using the short form of
the Demographics Standards of the German Society of Epidemiology [25]. Educational attainment was
estimated by recording years of school completed. With the Geriatric Nutritional Risk Index (GNRI),
the risk for malnutrition was assessed by measuring albumin, weight and height [26]. The Nutrition
Score, indicating the risk of general malnutrition, was calculated using the German short form of
the SCREEN II (Seniors in the Community: Risk Evaluation for Eating and Nutrition, version II)
questionnaire [27]. The physical activity assessment included the frequency and duration of activity
in summer and in winter [28]. Alcohol intake was assessed as daily average intake, based on the
last weekend and the last weekday, according to a validated recall method [29]. Multi-morbidity
was defined as suffering from two or more morbidities [30]. Information on smoking status was
based on self-report and participants were classified as never smokers, former smokers, or current
smokers [31]. The body mass index (BMI) was defined as the body mass (weight) measured in
kilograms divided by the square of the body height measured in meters. Frailty was defined according
to the five criteria proposed by Fried et al. [32] in a slightly modified way, depending on the availability
of information [33]. The glomerular filtration rate (eGFR) was estimated from serum creatinine as
an indicator of renal function [34]. Use of medications and supplements ingested in the last seven days
was collected through a database supported computer software (IDOM, Instrument for Databased
Assessment Of Medication) [35], together with the mode, dosage and frequency of ingestion [36].
The micronutrient composition of supplements was available from a database established by staff of
the Helmholtz Zentrum München. Polypharmacy was defined as the use of  5 medications, taken
regularly and prescribed (without herbal or homeopathic medications).
2.7. Statistical Analysis
Descriptive statistics for categorical variables were expressed as frequencies and percentages.
Due to non-normally distributed concentrations, serum levels of nutritional biomarkers were expressed
as median and interquartile range (IQR), from the first (Q1) to the third quartile (Q3). When biomarker
levels fell below the cut-offs for subclinical micronutrient deficiency, micronutrient status was
categorized as ‘subclinical deficiency’ for the respective micronutrient. Prevalence estimates of
subclinical micronutrient deficiency were reported with weighted percentages, using the Bavarian
population per 31 December 2015 for age and sex standardization (www.statistikdaten.bayern.
de/genesis/). Pearson’s chi-squared tests were conducted to assess sex and age differences in
prevalence estimates.
To investigate predictors of subclinical micronutrient deficiencies, we defined subclinical
micronutrient deficiency as the dependent variable and predictors as the categorical independent
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variables. The category with the ‘lowest risk’ was considered as reference for each independent
variable (e.g., male sex, 65–74 years, never smoker etc.). Participants with missing information in one
or more variables were excluded, except for frailty, which had a high number of missing values (n = 84).
To avoid deletion of numerous information-rich participants, all participants with missing frailty status
were considered as a separate category of the frailty variable. The analysis was performed separately
for 25OHD, folate, vitamin B12 and iron, according to the following scheme. We started with a binary
logistic regression, for each of the potential predictors, by calculating unadjusted odds ratios (ORs)
and 95% confidence intervals (CIs). Variables that were significant at p < 0.25 were considered for
inclusion in the multiple logistic regression model. Sex and age groups were forced into every model.
As simultaneous intake of multiple supplements is frequent among older adults, we considered, for
each nutritional biomarker, only supplement intake of the corresponding micronutrient. The final
model, with variables significant at p < 0.05, resulted from a stepwise selection procedure, which is
a combination of the forward and backward selection techniques. Model estimates are presented as
fully adjusted ORs along with 95% CIs. All analyses were performed using the statistical software
package, SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Baseline Characteristics of Study Participants
A description of baseline characteristics is shown in Table 1, stratified by sex. A total of
n = 1079 individuals, aged 65 to 93 years, participated in the study, including 542 (50.2%) women.
Overall, 47.7% of participants were physically inactive and 30.2% had a BMI   30 kg/m2, indicating
obesity. Current smokers accounted for less than 5% of the population. Only 4.6% of all individuals
were frail, but 37.9% were pre-frail. The prevalence of older adults having one or at least two diseases
was 24.7% and 66.8%, respectively. Noticeable sex differences were observed for the variables, family
status, educational level and alcohol consumption.
Table 1. Baseline characteristics of older adults in KORA-Age 2008/2009, stratified by sex.
Baseline Characteristics
All (n = 1079) Men (n = 537) Women (n = 542)
n % n % n %
Season of blood collection
Months of blood collection a
February–May 440 42.3 242 46.2 198 38.4
June–August 360 34.6 173 33 187 36.2
September–November 240 23.1 109 20.8 131 25.4
Socio-demographic factors
Age groups (years)
65–74 457 42.4 233 43.4 224 41.3
75–84 486 45 243 45.3 243 44.8
85–93 136 12.6 61 11.4 75 13.8
Family status b
Living with a partner 663 62.1 424 79.3 239 44.9
Living alone, divorced or widowed 404 37.9 111 20.8 293 55.1
Educational level (years)
Medium to high (10 to 17) 854 79.2 490 91.3 364 67.2
Low (8 to 9) 225 20.9 47 8.8 178 32.8
Lifestyle factors
Nutritional status
Geriatric Nutritional Risk Index
(GNRI) c
No risk (>98) 960 92.3 482 92.3 478 92.3
Low risk (92 to 98) 59 5.7 29 5.6 30 5.8
Moderate or major risk (<92) 21 2 11 2.1 10 1.9
Nutrition Score (SCREEN II) d
Low risk (41 to 48) 408 38.3 239 44.8 169 31.7
Medium risk (36 to <41) 377 35.4 181 34 196 36.8
High risk (<36) 281 26.4 113 21.2 168 31.5
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Table 1. Cont.
Baseline Characteristics
All (n = 1079) Men (n = 537) Women (n = 542)
n % n % n %
Physical activity e
Very active or moderately active 564 52.3 304 56.6 260 48.1
Less active or inactive 514 47.7 233 43.4 281 51.9
Alcohol consumption (g/day) f
0 393 36.6 126 23.5 267 49.7
>0 to <20 373 34.8 164 30.6 209 38.9
 20 307 28.6 246 45.9 61 11.4
Smoking status
Never smoker 617 57.2 204 38 413 76.2
Former smoker 413 38.3 303 56.4 110 20.3
Current smoker 49 4.5 30 5.6 19 3.5
Health factors
Body mass index (BMI) (kg/m2)
Normal (18.5 to <25) 228 21.1 99 18.4 129 23.8
Overweight (25 to <30) 525 48.7 281 52.3 244 45
Obese ( 30) 326 30.2 157 29.2 169 31.2
Frailty g
Non-frail 572 57.5 290 57.4 282 57.6
Pre-frail 377 37.9 194 38.4 183 37.4
Frail 46 4.6 21 4.2 25 5.1
Polypharmacy ( 5 medications)
No 712 66 356 66.3 356 65.7
Yes 367 34 181 33.7 186 34.3
eGFR (mL/min/1.73 m2)
Normal ( 60) 709 65.7 366 68.2 343 63.3
Low (<60) 370 34.3 171 31.8 199 36.7
Multi-morbidity h
No disease 91 8.5 56 10.5 35 6.6
One disease 263 24.7 138 25.9 125 23.4
Two or more diseases 712 66.8 338 63.5 374 70
Use of supplements
Vitamin D
Regular intake 140 13 36 6.7 104 19.2
No/irregular intake 939 87 501 93.3 438 80.8
Folic acid
Regular intake 116 10.8 51 9.5 65 12
No/irregular intake 963 89.3 486 90.5 477 88
Vitamin B12
Regular intake 114 10.6 48 8.9 66 12.2
No/irregular intake 965 89.4 489 91.1 476 87.8
Iron
Regular intake 36 3.3 15 2.8 21 3.9
No/irregular intake 1043 96.7 522 97.2 521 96.1
SCREEN II: Seniors in the Community Risk Evaluation for Eating and Nutrition, version II; eGFR: estimated
glomerular filtration rate; number of missing values: a 39, b 12, c 39, d 13, e 1, f 6, g 84, h 13.
Seniors regularly using supplements containing vitamin D, folic acid, vitamin B12 and iron
accounted for 6.7%, 9.5%, 8.9% and 2.8% of the male population, and 19.2%, 12.0%, 12.2% and 3.9% of
the female population, respectively. In these regular users, the median amounts of vitamin D, folic acid,
vitamin B12 and iron consumed from these supplements per day were, for men, 6.2 µg (IQR: 3.6–10.0),
400.0 µg (IQR: 200.0–714.3), 3.3 µg (IQR: 1.8–10.0) and 5.0 mg (IQR: 1.7–35.0), and for women 10.0 µg
(IQR: 5.0–20.0), 300.0 µg (IQR: 200.0–400.0), 3.0 µg (IQR: 1.5–9.0) and 4.0 mg (IQR: 3.5–5.0), respectively.
Serum concentrations of 25OHD, folate, vitamin B12 and iron were measured in n = 1040, n = 1043,
n = 1044 and n = 1050 KORA-Age individuals, respectively. Accordingly, a total of n = 39 (25OHD),
n = 36 (folate), n = 35 (vitamin B12) and n = 29 individuals (iron) had missing values in serum
nutritional biomarker measurements. Using Pearson’s chi-squared tests, KORA-Age individuals
with missing micronutrient values were more likely to be very old (85–93 years); to live alone, to be
divorced or widowed; to be less active or inactive; to be alcohol abstainers; to have a normal BMI
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(18.5  BMI < 25 kg/m2) and to have a low kidney function (eGFR < 60 mL/min/1.73 m2) (data
not shown).
3.2. Prevalence of Subclinical Micronutrient Deficiency
Serum concentrations of nutritional biomarkers and total age- and sex-standardized prevalence
of subclinical micronutrient deficiencies are presented in Table 2, stratified by sex.
Median concentrations of 25OHD, folate, vitamin B12 and iron were 48.3 nmol/L
(IQR: 31.4–69.6), 24.5 nmol/L (IQR: 18.2–33.3), 277 pmol/L (IQR: 214–376) and 16.1 µmol/L
(IQR: 13.1–20.0), respectively.
More than half of KORA-Age participants (52.0%) had low 25OHD concentrations.
In season-specific analyses, the prevalence of a subclinical vitamin D deficiency was 60.9% in
spring (February–May), 46.9% in summer (June–August) and 45.4% in fall (September–November).
The prevalence of a subclinical vitamin B12 deficiency (27.3%) was also high. Approximately 10% of
individuals had low levels of iron and folate. In sex-specific analyses, the prevalence of subclinical
deficiencies were more common in women for 25OHD (59.0% vs. 44.4%) and folate (9.4% vs. 8.0%)
and in men, for vitamin B12 (28.5% vs. 26.0%) and iron (13.5% vs. 8.4%). Using Pearson’s chi-squared
tests, these sex differences in prevalence were significant for 25OHD and iron (p < 0.001).
The prevalence of subclinical micronutrient deficiencies, by age groups, is shown in Figure 1.
The prevalence increased gradually with age for all micronutrients. Specifically, the proportion of
participants with serum 25OHD <50 nmol/L increased from 43.8% in the age group 65–74 years, to
74.2% in the age group 85–93 years. In Pearson’s chi-squared tests, divergences between age groups
were significant for all biomarkers (25OHD: p < 0.001; folate: p < 0.001; vitamin B12: p = 0.008; iron:
p = 0.001).
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3.3. Predictors of Subclinical Micronutrient Deficiency
As illustrated in Supplementary Tables S2 and S3, 15 variables were tested in a binary logistic
regression for the association between subclinical micronutrient deficiencies and each of the potential
predictors, plus the season of blood collection for 25OHD. Besides sex and age groups, common
potential predictors with p-values < 0.25 included educational level, nutritional status (Nutrition Score),
physical activity, alcohol consumption, frailty and use of micronutrient-containing supplements.
The final results of the multiple logistic regression analyses are shown in Table 3.
Common predictors that were significantly (p < 0.05) associated with low levels of several
micronutrients were identified. Seniors aged 85 and over had two times higher odds of having
low 25OHD (OR = 2.2, 95% CI 1.3–3.8, p = 0.003), low folate (OR = 2.3, 95% CI 1.2–4.3, p = 0.011)
and low vitamin B12 levels (OR = 2.0, 95% CI 1.2–3.2, p = 0.004) compared to their 65–74-year old
counterparts. Physical inactivity remained significantly associated with low 25OHD (OR = 1.6, 95%
CI 1.2–2.2, p = 0.001), low folate (OR = 2.0, 95% CI 1.2–3.4, p = 0.006) and low vitamin B12 levels (OR = 1.4,
95% CI 1.0–1.8, p = 0.042). Both pre-frailty and frailty were strong independent correlates of subclinical
25OHD and iron deficiency. Frailty increased four-fold, the odds of a subclinical iron deficiency,
compared to non-frail individuals (OR = 4.2, 95% CI 1.6–10.2, p = 0.002). Moreover, non/irregular
users of supplements, containing specific micronutrients, had four to five times higher odds of having
low 25OHD (OR = 4.8, 95% CI 3.1–7.6, p < 0.001), low folate (OR = 3.9, 95% CI 1.4–16.1, p = 0.024) and
low vitamin B12 levels (OR = 4.7, 95% CI 2.5–10.2, p < 0.001), compared to regular users.
A few predictors remained independently associated with low levels of specific micronutrients
only (Table 3). Springtime, female sex and obesity were significantly associated with a subclinical
25OHD deficiency. Former smokers had lower odds of having low 25OHD levels, compared to
non-smokers. Polypharmacy was associated with better vitamin B12 levels. Regarding folate, drinkers
of  20 g alcohol per day had lower odds of having low folate levels than non-drinkers. Finally,
having a moderate/major and even low risk for malnutrition (as assessed by the GNRI), male sex and
polypharmacy were associated with an increased risk for low iron levels.
N
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4. Discussion
The determination of the magnitude and predictors of subclinical micronutrient deficiency in
KORA-Age older adults revealed that the prevalence of subclinical vitamin D and B12 deficiencies
were high. Very old age, physical inactivity, frailty and no/irregular use of micronutrient-containing
supplements were common predictors of subclinical micronutrient deficiencies.
4.1. Prevalence of Subclinical Micronutrient Deficiency
Direct comparison of our findings with other studies is hampered by the lack of international
consensus as to which nutritional biomarker (biochemical and/or functional), which assay
methodology, and which cut off point should be used to define a subclinical micronutrient deficiency
in older adults [23,37]. Nevertheless, our population-based data is in line with previous studies that
have suggested that subclinical vitamin D and B12 deficiencies are prevalent public health problems
among older adults [12,15,38–42].
In the present study, low 25OHD levels were found in more than half (52.0%) of KORA-Age
participants, and were more frequent in women (59.0%) than in men (44.4%). These findings lie in the
range of national estimates from selected European countries that have used 25OHD < 50 nmol/L as the
cut-off, including Germany (women 69.9%, men 62.9%) [12], Austria (women 62.3%, men 64.8%) [38],
France (women 42.2%, men 36.5%) [39] and England (women 57.0%, men 49.0%) [15].
Around one out of four participants (27.3%) had a low vitamin B12 concentration in the KORA-Age
study population. In line with our data, a subclinical vitamin B12 deficiency has been reported in
10–15% of older adults aged 60 and over in the USA [40,41], and even in 23–35% of older adults aged
80 and over in the USA [42].
The prevalence of subclinical deficiencies for both serum folate and serum iron (~10%) was less
of a concern in the studied older adults. Recent studies in the USA [43] and in Brazil [44] pointed to
a prevalence of <5% for folate deficiency among older adults aged 60 and over, though it is important
to note that these countries have adopted national folic acid fortification policies. For serum iron,
comparable studies in older adults are lacking; other studies have focused on identifying more
advanced cases of iron deficiency or anemia, or they have used, in combination with serum iron or
without, other functional nutritional biomarkers of iron status, such as transferrin saturation, serum
ferritin, or blood hemoglobin measurements [45–47]. In these studies, the prevalence of iron deficiency
or anemia was only moderate (11%) in the older population.
Risk factors for subclinical micronutrient deficiency among older adults include: (i) decreased
energy needs due to a loss of lean body mass and a decline in physical activity; (ii) age-associated
physiological changes that affect absorption and utilization of micronutrients (e.g., decreased renal
production of the active vitamin D form by the aging kidney [8]), and finally (iii) the presence of
multiple chronic diseases, nutrient-drug interactions and variable diet quality, which may affect
micronutrient requirements [9,10]. To identify older adults who would benefit most from subclinical
micronutrient deficiency screening, we next discuss other factors that are associated with subclinical
micronutrient deficiencies among older adults.
4.2. Predictors of Subclinical Micronutrient Deficiency
4.2.1. Common Predictors of Subclinical Micronutrient Deficiency
Very Old Age
Seniors aged 85 and over were two times more likely to have low 25OHD, low folate and low
vitamin B12 levels compared to their younger counterparts. It is well known that micronutrient
inadequacies increase beyond 65 years [37,48], and even more in octogenarians and older [15,42].
The efficiency of producing vitamin D in the skin decreases with age [8], and may be coupled
to age-related factors that limit sunlight exposure, such as being more housebound. A subclinical
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vitamin B12 deficiency in older adults is mainly caused by inadequate dietary intake and malabsorption.
Chronic atrophic gastritis (a chronic inflammation causing loss of the gastric acid-producing cells,
which is prevalent in ~30% of older adults) and the intake of drugs, such as proton pump inhibitors,
histamine receptor 2 antagonists and biguanides, affect the secretion of gastric acid, thereby preventing
the release of vitamin B12 from foods. Other contributing risk factors for low vitamin B12 levels in older
adults include Helicobacter pylori infection and intestinal bacterial overgrowth [5,23]. An insufficient
folate status in older adults seems to be mainly due to poor diet [49].
Physical Inactivity
Physical inactivity was associated with low 25OHD, folate and vitamin B12 concentrations.
In epidemiological studies on vitamin D status, physical activity is often used as a proxy for time
spent outdoors and indirectly for sunlight exposure. Accordingly, housebound seniors and those
spending less time doing outdoor physical activity have decreased 25OHD levels [16]. Not surprisingly,
being physically active was associated with higher 25OHD levels in our study. It has to be noted that
our variable probably only gives a rough estimate of time spent outside, as it was not possible to
distinguish outdoor from indoor activities.
Brock et al. found a positive association between both outdoor and indoor physical activities and
25OHD, suggesting that physical activity per se may also be a surrogate for better general health [50].
This may explain the findings for folate and vitamin B12. Prospective studies are needed to confirm
a potential physiological link between physical activity and micronutrient concentrations.
Frailty
Pre-frail and frail individuals had a higher risk for subclinical 25OHD and iron deficiency.
Prior cross-sectional and prospective studies among KORA-Age participants found low 25OHD
levels to be associated with prevalent (pre-)frailty [33], incident pre-frailty and pre-frailty/frailty
combined [51]. To our knowledge, the relationship between low serum iron levels and frailty
occurrence has not been extensively investigated, yet Pires Corona et al. found that anemic older
adults with low hemoglobin levels were more likely to be frail [52].
Although our findings suggest that (pre-)frailty may be a predictor of a subclinical micronutrient
deficiency, it has also been suggested that poor nutrition itself can favor the development of frailty [53].
No/Irregular Use of Supplements
No/irregular use of supplements was a strong common predictor of subclinical 25OHD and
folate and vitamin B12 deficiencies. Prior studies in older adults have found that supplement use is
a major predictor of vitamin D status [14,17] and is linked to higher vitamin B12 and folate levels [54,55].
Although 44.7% of KORA-Age participants used supplements containing vitamins or minerals [36],
only around 10% took supplements containing vitamin D, folate and vitamin B12, respectively.
As shown previously [56,57], optimal serum micronutrient levels, such as vitamin D, folate and
vitamin B12, can be maintained by supplementation. The possibility that regular supplementation with
these specific micronutrients might help older adults in satisfying their requirements, and prevent
chronic diseases via the correction of low levels, as found earlier [56], is of major interest and could
stimulate research on biological pathways that link supplement intake, micronutrient status and
disease state.
No/irregular use of iron-containing supplements was not significantly associated with
a subclinical iron deficiency in our study. It is important to note that there are concerns about
the adverse effects of iron-containing supplements [6], including nausea, epigastric discomfort and
constipation, all of which are dose-related. In case of iron deficiency anemia, it is recommended to
seek consultation from a physician, in order to use appropriately dosed iron-containing supplements.
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4.2.2. Further Predictors of Subclinical Micronutrient Deficiency
Vitamin D (Springtime, Female Sex, Obesity, Former Smoking)
In line with previous studies among older adults, we found that springtime, female sex and
obesity were significantly associated with low 25OHD levels [15–17]. Seasonal variations in 25OHD
status are well known. During cold and dark months, older adults may spend more daylight hours
indoors, resulting in less sun exposure. Furthermore, in Germany, from October to March, UVB
radiation is too low to induce vitamin D synthesis by the skin [58]. Sex differences may be due
to unaccounted confounders, such as clothing style, use of sun protection, and to dietary intake.
Concerning the inverse association with obesity, it has been suggested that vitamin D is accumulated
in adipose tissue, resulting in decreased bioavailability and lower circulating 25OHD levels in the
blood of obese persons [59].
The investigation of smoking status yielded inconsistent results. In studies classifying former
smoking as a separate category [15,60], former smoking was not found to be a significant predictor of
low 25OHD levels. In our data, former smoking was associated with higher 25OHD levels than never
smokers. Schwab et al. showed that former smokers, among KORA-Age individuals, were two times
more likely to ingest vitamin and mineral-containing supplements compared to never smokers [36].
It is therefore conceivable that smoking cessation went along with improved diet and lifestyle habits
that increased vitamin D intake. These unaccounted factors, such as improved intake of foods rich
in micronutrients or longer times spent outdoors, may have confounded the observed association.
Furthermore, there is always the possibility for a type I error due to multiple comparisons.
Vitamin B12 (No Polypharmacy)
Some drugs reduce absorption or affect the metabolism of vitamin B12 via known mechanisms
(such as proton pump inhibitors or histamine receptor 2 antagonists) or unknown mechanisms (such as
metformin) [23]. Conversely, we found that polypharmacy was associated with sufficient vitamin B12
levels. Differentiating between the different types of medications ingested was outside the scope of
this analysis, but it would be interesting to find out which medication(s) may positively impact on
vitamin B12 status.
Folate (Alcohol Consumption)
Contra-intuitively, drinkers of  20 g alcohol per day had higher folate levels than abstainers.
The consumption of  20 g of alcohol is equivalent to  0.5 L beer,  0.2 L wine or  3 small spirits
of 2 cL [61], and was more frequent in men (n = 246) than women (n = 61) (Table 1). Differentiating
between alcohol levels revealed that the majority of these female (n = 54) and male drinkers (n = 163)
used between  20 and <40 g/day, which is still considered as moderate drinking for men. A lower
proportion of men were high (between  40 to <60 g/day, n = 60) to heavy drinkers (>60 g/day, n = 23),
respectively. Our variable category thus mostly covered moderate to high drinkers, and only a few
heavy drinkers.
In observational epidemiological studies in humans, folate deficiency has been shown to be
common in excessive alcohol drinkers and alcoholics [62], suggesting that alcohol consumption may
affect folate status preponderantly at higher alcohol doses. Also, light to moderate alcohol consumption
is known to be associated with a reduction in all-cause mortality [61]. It is thus possible that the dose
at which alcohol was consumed in our study—mostly moderate amounts—was not harmful, but had
a positive effect on health in general, thereby possibly affecting folate status. Possible mechanisms
involved need further investigation. Nonetheless, caution is warranted as the observed association
with alcohol use might be confounded by other factors that influence both traits. Another possible
explanation for this counter-intuitive finding is the selection bias associated with the follow-up design
of the KORA-Age study, whereby more health-interested individuals involved in former KORA studies,
and probably fewer sick individuals with reduced alcohol consumption levels, participated.
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Iron (Male Sex, GNRI, Polypharmacy)
Participants with a moderate/major and even low risk for malnutrition (GNRI) were at higher risk
for low iron levels. The GNRI is a nutrition-related risk index that can predict the risk for morbidity and
mortality in hospitalized older adults, in relation to malnutrition-associated pathologies. Our finding
suggests that the GNRI may be a marker for subclinical iron deficiency in older adults. However, as the
GNRI has primarily been established for use in hospitalized older adults, it may not necessarily be
appropriate among community-dwelling older adults. Further research is warranted in this regard [26].
Men were at higher odds of having low iron levels, despite having higher median iron
concentrations than women (Table 2). Sex divergence may be due to the use of a higher cut-off
for men, as recommended in the literature [24]. Moreover, serum iron may increase after the ingestion
of iron-containing foods [6], suggesting that sex differences may also be due to unequal dietary intakes.
Finally, polypharmacy was inversely associated with iron status. Iron status in older adults is known to
be affected by a number of medications [6], including antacids and proton pump inhibitors. Knowing
which medication type may reduce iron levels is of interest from a prevention point of view and needs
further research.
4.3. Strengths and Weaknesses
The KORA-Age study is singular in the sense that it includes a large (>1000 participants) and
socio-demographically representative sample of old, and even very old, adults in Germany. Caution is
warranted when generalizing findings on a national level, as possible regional differences in eating
habits and latitude may exist. The assessment of multiple predictors of subclinical micronutrient
deficiency was rendered possible by the extensive health assessment of participants and the quality of
the KORA-Age data, which has been collected by trained interviewers and systematically controlled
before entry into the KORA-Age database.
The use of biomarkers of micronutrient status is both a strength and a limitation of our study.
Nutritional biomarkers may not necessarily reflect the amount of micronutrient intake from foods, and
may be affected by multi-morbidity, inflammation and nutrient-drug interactions, especially in older
adults. Nevertheless, biomarkers relate to the nutritional status of micronutrients after absorption in
the body, and can directly reflect subclinical deficiency at the blood level.
Certain laboratory procedures, used for the assessment of micronutrient status were not the ‘gold
standard’, e.g., the immunoassay procedure used in this study versus the commonly used Lactobacillus
rhamnosus microbiological assay for measuring serum folate levels [22]. Also, the use of serum iron
levels for the evaluation of iron status may be misleading because they are subject to diurnal rhythms
and increase after the ingestion of iron-containing foods. However, serum iron concentrations indicate
the adequacy of the iron supply to developing red blood cells [6], and may be used as a screening tool
for a subclinical deficiency, as opposed to an established clinical deficiency. To identify more advanced
cases of iron deficiency or anemia, additional measurements that use functional nutritional biomarkers
are essential, including serum/plasma soluble transferrin receptor, serum/plasma ferritin, or blood
hemoglobin measurements [22].
Another limitation arises from the cross-sectional design of this analysis, which precludes
any direct cause-effect relationships between subclinical micronutrient deficiency and predictors.
Also, causality cannot be definitively proven, owing to the possible correlation with other unknown
or unmeasured predictors. Yet, a causal effect in one or the other direction is possible and has to be
further examined in prospective studies.
5. Conclusions
Using serum nutritional biomarkers, determination of the magnitude of subclinical vitamin D,
folate, vitamin B12 and iron deficiencies, among KORA-Age older adults, revealed that more than half of
individuals had low 25OHD levels and more than a quarter had low vitamin B12 levels. The prevalence
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of subclinical deficiencies for both folate and iron (~10%) were less of a concern. Very old age, physical
inactivity, frailty and no/irregular use of micronutrient-containing supplements were identified as
common predictors of subclinical micronutrient deficiencies in the studied older adults.
Our findings provide further rationale for screening subgroups at high-risk for subclinical
micronutrient deficiencies. The possibility that regular and appropriately dosed micronutrient
supplementation might help older adults otherwise unable to follow dietary guidelines in satisfying
their requirements, and prevent chronic diseases via the correction of low micronutrient levels, is
of major interest and could stimulate research on biological pathways that link supplement intake,
micronutrient status and disease state.
Supplementary Materials: The following are available online at www.mdpi.com/2072-6643/9/12/1276/s1,
Figure S1: Flowchart of the KORA-Age 2008/2009 recruitment and retention profile, Table S1: Description of
data collection and categorization methods for the investigated predictors in KORA-Age 2008/2009, Table S2:
Unadjusted ORs with 95% CIs for subclinical micronutrient deficiencies by categories of potential predictors:
Results from binary logistic regression analyses in KORA-Age 2008/2009, Table S3: Predictors with p < 0.25 in
binary logistic regression which were entered into each multiple logistic regression model.
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Abstract
Effects of low serum 25OHD on age-related changes in muscle mass and function remain unclear. Our aims were to explore 
associations of baseline 25OHD levels with prevalent and incident sarcopenia and changes in muscle parameters, and to 
examine the role of parathyroid hormone (PTH) therein. Cross-sectional (n = 975) and prospective analyses (n = 702) of 
older adults aged 65–93 years participating in the KORA-Age study. Sarcopenia was defined using the 2010 European 
Working Group on Sarcopenia in Older People (EWGSOP) criteria as low muscle mass combined with low grip strength or 
low physical performance. Associations with baseline 25OHD were examined in multiple regression analyses. Low vitamin 
D status was linked to increased odds of prevalent sarcopenia. Over three years, low baseline 25OHD < 25 vs. ≥ 50 nmol/L 
were associated with greater loss of muscle mass and increased time for the Timed Up and Go test. The risk for developing 
incident sarcopenia was not significantly elevated in individuals with low baseline 25OHD but when including death as 
combined outcome alongside incident sarcopenia, there was a strong positive association in multivariable analysis [OR (95% 
CI) 3.19 (1.54–6.57) for 25OHD < 25 vs. ≥ 50 nmol/L]. There was no evidence for a PTH-mediating effect. Low baseline 
25OHD levels were associated with unfavorable changes in muscle mass and physical performance, but not with incident 
sarcopenia. Future randomized trials are needed to assess causality and to address the issue of competing risks such as 
mortality in older cohorts.
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Introduction
Conceptualized as a geriatric syndrome of the gradual loss 
of muscle mass and function, sarcopenia becomes increas-
ingly common in older age and often occurs simultane-
ously with low serum 25-hydroxyvitamin D (25OHD) 
levels [1]. Both conditions are linked to common clinical 
geriatric outcomes, including muscle weakness, falls and 
frailty [2].
There are several reasons to consider how vitamin D 
may have a beneficial effect on muscle health, yet indi-
vidual observational studies examining the relationship of 
25OHD levels with sarcopenia and related muscle param-
eters have yielded inconsistent results and the number of 
prospective studies is limited. We are aware of only two 
prospective studies that have examined 25OHD in relation 
to the incidence of sarcopenia defined by both low muscle 
mass and low muscle function. While the first study did 
not observe a significant association between vitamin D 
status and incident sarcopenia [3], low levels of 25OHD 
were associated with a significant increased risk of inci-
dent sarcopenia in the second one [4]. Furthermore, low 
25OHD levels were not linked to change in muscle mass 
over time [3, 5, 6]. In some prospective studies, lower 
25OHD levels were associated with loss of muscle func-
tion such a muscle strength or physical performance [5–8], 
while others did not find respective associations [3, 9–11].
The mechanisms by which vitamin D status may affect 
muscle metabolism and function are not fully elucidated 
[12]. They may be both direct, via activation of a vitamin 
D receptor on muscle tissue by the biologically active form 
of vitamin D [13], and indirect, via effects of low serum 
calcium [14], low serum phosphate [15] or increased 
serum parathyroid hormone (PTH) levels [6].
We used cross-sectional and prospective data from the 
population-based KORA (Cooperative Health Research 
in the Region of Augsburg)-Age study to determine the 
associations of baseline 25OHD levels with prevalent and 
incident sarcopenia as well as changes in related muscle 
parameters in German older adults. The role of PTH as a 
potential mediator was also examined.
Methods
Study Design and Participants
We used data from two time points of the KORA-Age 
study (baseline: 2008/2009; follow-up: 2012). Full details 
about the study design and participants have been pub-
lished previously [16]. Briefly, the cohort includes 1079 
eligible participants aged ≥ 65 years on 31.12.2008, who 
participated in a multidimensional health assessment at 
baseline. A total of 975 individuals with complete health 
assessment and without hypercalcemia at baseline (serum 
calcium levels > 2.6 mmol/L) were included in cross-sec-
tional analyses. After exclusion of individuals with sarco-
penia at baseline, without follow-up data or with missing 
information on sarcopenia at follow-up, a total of 702 par-
ticipants were included in prospective analyses. Of those 
without follow-up data (n = 179), 57 died and 122 did not 
participate due to other reasons. The Ethics Committee 
of the Bavarian Medical Association approved the study 
protocol (reference number: 08064), and written informed 
consent was obtained from all participants.
Sarcopenia and Related Muscle Parameters
Sarcopenia status was assessed at baseline and follow-up 
using the European Working Group on Sarcopenia in Older 
People (EWGSOP) 2010 criteria: low muscle mass com-
bined with either low muscle strength or low physical per-
formance [17].
Muscle mass was assessed using bioimpedance values 
measured with a body impedance analyzer (BIA 2000-S; 
Data Input GmbH, Frankfurt, Germany) [18]. Calibration 
of the BIA device occurred every day before and after the 
last use of the device with the test resistor. Results of the 
calibration were systematically documented and compared 
to target values of resistance: R = 500 Ω (± 4) and reac-
tance Xc = 144 Ω (± 4). The multiple regression prediction 
equation developed by Janssen et al. was applied to esti-
mate skeletal muscle mass [19]. Muscle mass index (kg/
m2) was then calculated as skeletal muscle mass divided by 
height-squared. For low muscle mass index, we used cut-offs 
previously published in KORA-Age: ≤ 8.72 kg/m2 in men 
and ≤ 6.33 kg/m2 in women [20].
Handgrip strength (kg) was assessed using the JAMAR 
handheld dynamometer (Saehan Corp., Masan, Korea). The 
mean value of three measurements in the participant’s domi-
nant hand was taken for analyses. We applied the EWGSOP 
cut-offs for low grip strength < 30 kg in men and < 20 kg in 
women [17].
Gait speed (m/sec), assessed using the GAITRite system 
(CIR Systems, Havertown, PA, USA) [21], was used as the 
primary measure of physical performance. The standard cut-
off of ≤ 0.8 m/s of the normal walking speed was applied for 
defining slow gait speed [17]. We also repeated all analyses 
using the time to complete the Timed Up and Go (TUG) 
test as an alternative measure of physical performance. The 
TUG test (sec) measured the time taken to stand up from a 
standard chair, walk a distance of 3 m, turn, walk back to the 
chair and sit down. More time needed to complete the TUG 
test was defined as completing the test in ≥ 13.74 s. This 
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cut-point corresponds to the same proportion of individuals 
from the total baseline sample below ≤ 0.8 m/s for the gait 
speed (14.3%).
Serum 25OHD and PTH Levels
Non-fasting blood samples were taken at baseline between 
February and November 2009 at the KORA study center, 
usually between 07:30 am and 11:00 am, and drawn into 
serum gel S-Monovette tubes (Sarstedt, Nümbrecht, Ger-
many). Blood was gently inverted twice and rested for 
30 min at room temperature until complete coagulation. 
After centrifugation at 15 °C for 10 min, the serum obtained 
was aliquoted into Nunc cryotubes (Thermo Fisher Scien-
tific, Waltham, MA, USA). For the analysis of both vitamin 
D and PTH status, serum probes were frozen at − 80 °C at 
the KORA study center, transported on ice and stored at a 
minimum of − 80 °C until analysis in partner laboratories. 
Serum concentrations of 25OHD and PTH were measured 
by an electrochemiluminescence immunoassay (ECLIA) 
using the Vitamin D total test (Elecsys 2011, Roche, Ger-
many) and the intact PTH (1–84) test (Elecsys 2011, Roche, 
Germany), respectively. Intra- and inter-assay coefficients 
of variations were < 5% and < 10% for 25OHD, and < 5% 
and < 5% for PTH, respectively. Vitamin D status was cat-
egorized as deficiency (< 25 nmol/L), insufficiency (25 
to  < 50 nmol/L) and sufficiency (≥ 50 nmol/L, reference) 
[22]. Due to the lack of consistent reference ranges [23], 
PTH levels were categorized as 1st tertile (< 2.8 pmol/L, 
reference), 2nd tertile (2.8 to  < 3.8 pmol/L) and 3rd tertile 
(≥ 3.8 pmol/L).
Confounders
To avoid bias by adding covariates to the model that are 
intermediate factors or common effects, we constructed a 
directed acyclic graph (DAG) to identify relevant confound-
ers in the association of vitamin D status with sarcopenia 
[24]. Using the graphical tool DAGitty [25], we identified a 
minimal adjustment set of covariates needed to estimate the 
causal effect without confounding: sex, age, Nutrition Score 
(SCREEN II), physical activity, BMI and use of vitamin D 
supplements. The variables—sex and age—were collected 
using the short form of the Demographics Standards of the 
German Society of Epidemiology [26]. The Nutrition Score, 
indicating risk of general malnutrition, was calculated using 
the German short form of the SCREEN II (Seniors in the 
Community: Risk Evaluation for Eating and Nutrition, ver-
sion II) questionnaire [27]. Participants were classified as 
“low risk” (score 41–48), “moderate risk” (score 36 to  < 41) 
or “high risk of malnutrition” (score < 36). Physical activity 
assessment included frequency and duration of activity in 
summer and winter [28]. Possible answers were (1) > 2 h/
week, (2) 1–2 h/week, (3) < 1 h/week and (4) none. Par-
ticipants, who had a total score < 5, obtained by summing 
the numbers (1)–(4) relating to winter and summer, were 
classified to be “physically active”, all others were clas-
sified as “inactive”. Body mass index (BMI) was defined 
as body weight (kg) divided by height-squared  (m2). Use 
of supplements ingested in the last 7 days was collected 
through a database supported computer software (IDOM, 
Instrument for Databased Assessment Of Medication) [29], 
together with the mode, dosage and frequency of ingestion 
[30]. Vitamin D supplement use was classified as “regular 
intake” or “no/irregular intake”. The DAG with method-
ology and references can be seen in the Online Resource 
Fig. 1 (available in Calcified Tissue International online). 
Methods used to collect and categorize other baseline—not 
DAG confounders—variables (e.g. alcohol intake, smoking 
status, polypharmacy) have been described elsewhere [31].
Statistical Analysis
Baseline descriptive characteristics were expressed as 
mean ± standard deviation (SD), median (1st quartile–3rd 
quartile) or proportion (%) by sarcopenia status at base-
line and were compared across categories using one-way 
ANOVA or Kruskal–Wallis tests for continuous variables 
and Pearson’s χ2 tests for categorical variables.
In cross-sectional analyses (n = 975), multiple logistic 
regression analyses tested the associations of categorized 
baseline 25OHD levels with the prevalence of sarcopenia 
and related muscle parameters, and in prospective analy-
ses (n = 702) with the incidence of sarcopenia and related 
muscle parameters in individuals without the respective 
condition at baseline. We repeated the prospective analyses 
using a combined endpoint of incident sarcopenia or death, 
assuming that many of those who died before the follow-up 
examination developed sarcopenia prior to death. Results 
were expressed as odds ratios (OR) with 95% confidence 
interval (CI). Annual change (%) in each muscle parameter 
was calculated as: [(follow-up-baseline)/baseline)*(100/
time)]. By visual inspection of normal plots (histograms) 
and Q–Q plots, annual change in each muscle parameter 
was normally distributed. Multiple linear regression analy-
ses tested the associations of baseline 25OHD with annual 
changes in muscle parameters. Results were expressed as 
β-coefficients with 95% CIs.
In all analyses, three adjusted models were fitted: Model 1 
was adjusted for age and sex, Model 2 was fully adjusted for 
DAG confounders: age, sex, Nutrition Score (SCREEN II), 
physical activity, BMI and use of vitamin D supplements, 
and Model 3 was fully adjusted plus additional inclusion of 
PTH tertiles to test the potential mediating effect of PTH. 
A p value < 0.05 was considered statistically significant. 
All statistical analyses were performed using the statistical 
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software package, SAS version 9.4 (SAS Institute Inc., Cary, 
NC, USA).
Results
Participant Characteristics
Baseline characteristics of the 975 individuals (49.2% 
female, mean age 75.7 ± 6.5 years) included in cross-sec-
tional analyses are shown in Table 1 stratified by sarcopenia 
status.
Overall, 6.7% of individuals had prevalent sarcopenia 
(2.3% in men, 4.4% in women). When using the TUG test 
as an alternative to gait speed, the prevalence of sarcopenia 
minimally decreased to 6.6% (2.3% in men, 4.3% in women). 
Sarcopenic individuals were more likely to be female, older, 
to live alone, be divorced or widowed, to be physically inac-
tive, to have a lower BMI and lower 25OHD levels.
Cross-sectional Results
At baseline, individuals with low baseline 25OHD < 25 
vs. ≥ 50 nmol/L tended to have higher odds of prevalent 
sarcopenia in fully adjusted analysis [OR (95% CI) 2.14 
(0.98–4.63)]. Additional inclusion of PTH tertiles strength-
ened the association, which became significant [OR (95% 
CI): 2.64 (1.16–5.98)]. Vitamin D deficiency was associ-
ated with higher odds of low grip strength, slow gait speed 
and more time needed for the TUG test after multivariable 
adjustment (Table 2).
Prospective Results
Annual changes in muscle parameters are shown in Table 3 
stratified by baseline 25OHD levels. In fully adjusted 
analysis, individuals with low baseline 25OHD < 25 
vs. ≥ 50 nmol/L had a 0.94% greater annual decrease in mus-
cle mass index and a 3.06% greater annual increase in time 
to complete the TUG test. Vitamin D status was not signifi-
cantly associated with change in grip strength or gait speed.
After 2.9 ± 0.1 years of follow-up, 4.3% of individuals 
without sarcopenia at baseline developed incident sarcope-
nia (2.8% in men; 5.8% in women). The incidence of sarco-
penia remained unchanged when using the TUG test as an 
alternative to gait speed. Lower baseline 25OHD levels were 
not significantly associated with the risk for developing inci-
dent sarcopenia. Adjustment for PTH tertiles slightly attenu-
ated the observed trends (Table 4). When repeating analyses 
using a combined endpoint of incident sarcopenia or death, 
11.5% of individuals developed the outcome. The presence 
of both vitamin D deficiency and insufficiency were strongly 
associated with a higher risk for incident sarcopenia or death 
[deficiency: OR (95% CI) 3.19 (1.54–6.57); insufficiency: 
OR (95% CI) 1.84 (1.06–3.22)]. Vitamin D insufficiency 
was associated with a higher risk for developing low muscle 
mass index after multivariable adjustment (Table 4).
Discussion
In this 3-year prospective study among German older adults, 
low baseline 25OHD < 25 vs. ≥ 50 nmol/L were significantly 
associated with changes in muscle mass and physical per-
formance as assessed by the time to complete the TUG 
test. Vitamin D status was not associated with the risk for 
developing incident sarcopenia. However, when including 
death as a combined outcome alongside incident sarcopenia, 
there was a strong positive association with low baseline 
25OHD < 25 vs. ≥ 50 nmol/L. There was no evidence for a 
mediating effect of PTH.
25OHD and Changes in Muscle Mass and Physical 
Performance
In previous prospective studies, low 25OHD levels were not 
linked to change in muscle mass [3, 5, 6]. Some studies have 
shown, however, an association with loss of muscle strength 
[5, 6, 8]. Findings on the association between 25OHD and 
decline in gait speed have relatively consistently shown no 
significant association [3, 10, 11]. In our study, gait speed 
increased with a mean annual gain of 2.95 ± 8.12%, possi-
bly due to the selection bias in KORA-Age, whereby more 
healthy individuals participated at follow-up [32]. However, 
caution is warranted when interpreting our gait speed vari-
able because a comparable effect was not seen for the TUG 
test. Studies investigating vitamin D in relation to change in 
other performance tests, including the TUG test, have shown 
either no association [9–11] or a greater decline in physical 
performance among those with low baseline 25OHD [7, 33].
Meta-analyses of randomized controlled trials (RCTs) 
have shown heterogeneous effects of vitamin D supplemen-
tation on muscle parameters. One meta-analysis of 13 tri-
als in older adults aged ≥ 60 years has shown evidence of 
decreased time to complete the TUG test and gains in lower 
extremity strength, but no beneficial effect on gait speed 
[34]. Another larger meta-analysis of 30 trials in individuals 
with mean age 61.1 years found a small positive effect on 
muscle strength but not on muscle mass [35]. More recently, 
a meta-analysis of 15 studies in individuals aged ≥ 65 years 
demonstrated no improvement in muscle strength after 
vitamin D administration [36]. Further, RCTs that compare 
effects of vitamin D supplementation in sarcopenic ver-
sus non-sarcopenic participants are needed to confirm the 
place of vitamin D supplementation in the management of 
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Table 1  Participant 
characteristics by sarcopenia 
status at baseline, n = 975
All
n = 975
No sarcopenia
n = 910
Sarcopenia
n = 65
p value
Socio-demographic factors
 Women (%) 480 (49.2) 437 (48.0) 43 (66.2) 0.005
 Age (years) 75.7 ± 6.5 75.3 ± 6.4 81.0 ± 6.4 < 0.001
  Categorized (%) < 0.001
   65–74 434 (44.5) 422 (46.4 12 (18.5)
   75–84 435 (44.6) 403 (44.3 32 (49.2)
   85 + 106 (10.9) 85 (9.3 21 (32.3)
 Family status (%) < 0.001
  Living with a partner 617 (63.8) 590 (65.2) 27 (43.6)
  Living alone, divorced or widowed 350 (36.2) 315 (34.8) 35 (56.5)
 Low educational level (%) 195 (20.0) 183 (20.1) 12 (18.5) 0.748
Lifestyle factors
 Nutrition Score (SCREEN II),  % 0.317
  Low risk (41 to 48) 381 (39.1) 360 (39.6) 21 (32.3)
  Medium risk (36 to < 41) 350 (35.9) 327 (35.9) 23 (35.4)
  High risk (< 36) 244 (25.0) 223 (24.5) 21 (32.3)
 Physically inactive (%) 442 (45.3) 404 (44.4) 38 (58.5) 0.028
 Alcohol  consumptiona (%) 0.008
  Abstainer 340 (34.9) 306 (33.7) 34 (52.3)
  Light-moderate drinker 500 (51.3) 477 (52.5) 23 (35.4)
  High drinker 134 (13.8) 126 (13.9) 8 (12.3)
 Smoking (%) 0.286
  Never smoker 555 (56.9) 512 (56.3) 43 (66.2)
  Ex-smoker 373 (38.3) 353 (38.8) 20 (30.7)
  Current smoker 47 (4.8) 45 (5.0) 2 (3.1)
Health factors
 BMI (kg/m2) 28.5 ± 4.3 28.7 ± 4.2 24.9 ± 3.1 < 0.001
 Polypharmacy (≥ 5 medications) (%) 304 (31.2) 284 (31.2) 20 (30.8) 0.941
eGFR < 60 mL/min/1.73 m2b (%) 381 (39.1) 351 (38.6) 30 (46.2) 0.229
 Multimorbidityc (%) 0.259
  No disease 89 (9.2) 86 (9.5) 3 (4.7)
  One disease 251 (25.9) 237 (26.2) 14 (21.9)
  Two or more diseases 629 (64.9) 582 (64.3) 47 (73.4)
 Vitamin D supplements (%) 0.500
  Regular use 132 (13.5) 125 (13.7) 7 (10.8)
  No/irregular use 843 (86.5) 785 (86.3) 58 (89.2)
 Calcium supplements (%) 0.642
  Regular use 139 (14.3) 131 (14.4) 8 (12.3)
  No/irregular use 836 (85.7) 779 (85.6) 57 (87.7)
Biological measures
 Season of blood collection (%) 0.278
  Jun–Aug 341 (35.0) 324 (35.6) 17 (26.2)
  Sep–Nov 215 (22.1) 200 (22.0) 15 (23.1)
  Feb–May 419 (43.0) 386 (42.4) 33 (50.8)
 25OHD (nmol/L) 48.9 31.9–69.9 49.0 32.7–70.6 41.4 24.4–67.1 0.025
  Categorized (%) 0.002
   Sufficiency (≥ 50) 468 (48.0) 443 (48.7) 25 (38.5)
   Insufficiency (25- < 50) 369 (37.9) 348 (38.2) 21 (32.3)
   Deficiency (< 25) 138 (14.2) 119 (13.1) 19 (29.2)
 PTH, pmol/L 3.3 2.5-4.1 3.3 2.5–4.1 3.1 2.5–4.3 0.923
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Table 1  (continued) All
n = 975
No sarcopenia
n = 910
Sarcopenia
n = 65
p value
  Categorized,  % 0.466
   1st Tertile (< 2.8) 326 (33.4) 302 (33.2) 24 (36.9)
   2nd Tertile (2.8 to  < 3.8) 323 (33.1) 306 (33.6) 17 (26.2)
   3rd Tertile (≥ 3.8) 326 (33.4) 302 (33.2) 24 (36.9)
  Hyperparathyroidism (≥ 6.8) (%) 55 (5.6) 50 (5.5) 5 (7.7) 0.458
Sarcopenia-related muscle parameters
 Muscle mass  indexd (kg/m2) 8.8 ± 1.7 8.9 ± 1.6 6.6 ± 1.3 < 0.001
 Grip strength (kg) 26.8 ± 9.7 27.5 ± 9.6 17.9 ± 6.6 < 0.001
 Gait  speede (m/s) 1.1 ± 0.2 1.1 ± 0.2 1.0 ± 0.2 0.0311
 Walking  aidf (%) 45 (5.0) 43 (5.1) 2 (3.9) 0.695
 Time to complete the TUG  testg (s) 9.8 8.5–11.9 9.7 8.5–11.9 10.6 9.2–12.5 0.060
Statistically significant values are highlighted in bold (p < 0.05)
Results expressed as mean ± SD, median  (1st quartile-3rd quartile) or proportion (%)
Number of missing values: a1; b1; c6; d18; e74; f74; g62
25OHD 25-hydroxyvitamin D, PTH parathyroid hormone, TUG test Timed Up and Go Test, SD standard 
deviation
Table 2  Cross-sectional associations of baseline 25OHD levels with the prevalence of sarcopenia and related muscle parameters, n = 975
Statistically significant values are highlighted in bold (p < 0.05)
Results of multiple logistic regression analyses expressed as OR (95% CI): Model 1 adjusted for sex and age, Model 2 fully-adjusted for DAG 
confounders: sex, age, Nutrition Score (SCREEN II), physical activity, BMI and use of vitamin D supplements; Model 3 fully-adjusted plus PTH 
tertiles; *p < 0.05 versus ref, **p < 0.01 versus ref
25OHD 25-hydroxyvitamin D categorized as deficiency (< 25 nmol/L), insufficiency (25 to < 50 nmol/L) and sufficiency (≥ 50 nmol/L, ref), 
PTH parathyroid hormone, TUG test Timed Up and Go test, DAG, directed acyclic graph, OR odds ratio, CI confidence interval
Outcome at baseline (dichoto-
mized)
25OHD Prevalence of 
outcome (%)
n OR (95% CI)
Model 1: Age and sex Model 2: Fully-adjusted Model 3: Model 2 + PTH
Sarcopenia All 6.7 975
Deficiency 13.8 138 1.52 (0.76–2.99) 2.14 (0.98–4.63) 2.64 (1.16–5.98)*
Insufficiency 5.7 369 0.84 (0.45–1.55) 0.96 (0.49–1.85) 0.99 (0.50–1.93)
Sufficiency 5.3 468 1.00 (ref) 1.00 (ref) 1.00 (ref)
Low muscle mass index All 10.3 957
Deficiency 15.2 138 1.02 (0.55–1.83) 1.70 (0.82–3.44) 2.12 (1.00–4.45)*
Insufficiency 9.1 362 0.76 (0.46–1.23) 0.96 (0.55–1.64) 1.02 (0.56–1.77)
Sufficiency 9.9 457 1.00 (ref) 1.00 (ref) 1.00 (ref)
Low grip strength All 38.4 975
Deficiency 57.3 138 1.52 (0.99–2.35) 1.59 (1.00–2.52)* 1.52 (0.95–2.43)
Insufficiency 38.5 369 1.02 (0.75–1.39) 1.04 (0.75–1.43) 1.02 (0.74–1.41)
Sufficiency 32.7 468 1.00 (ref) 1.00 (ref) 1.00 (ref)
Slow gait speed All 13.8 901
Deficiency 27.3 110 2.77 (1.55–4.9)** 2.33 (1.26–4.30)** 2.36 (1.26–4.41)**
Insufficiency 16.6 349 1.93 (1.23–3.06)** 1.89 (1.16–3.12)* 1.90 (1.16–3.14)
Sufficiency 8.1 442 1.00 (ref) 1.00 (ref) 1.00 (ref)
More time needed to complete 
the TUG test
All 13.6 913
Deficiency 28.0 118 3.05 (1.71–5.42)** 2.31 (1.25–4.28)** 2.13 (1.13–3.99)*
Insufficiency 16.5 351 2.12 (1.34–3.42)** 1.94 (1.18–3.23)* 1.97 (1.19–3.29)*
Sufficiency 7.4 444 1.00 (ref) 1.00 (ref) 1.00 (ref)
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sarcopenia, and to clarify optimal 25OHD levels for muscle 
health.
25OHD and Incident Sarcopenia or Death
Very few prospective studies have examined vitamin D sta-
tus in relation to incident sarcopenia. In one study conducted 
among 433 men aged ≥ 60 years, the risk for developing inci-
dent sarcopenia over 4.3 years was not significantly related 
to baseline 25OHD in multivariable analysis [3]. Another 
study following a cohort of 709 men aged ≥ 70 years over 
5 years showed that baseline 25OHD < 40 vs. ≥ 68.9 nmol/L 
were significantly associated with increased odds of inci-
dent sarcopenia with an OR (95% CI) of 2.53 (1.14–5.64) 
[4]. Comparison of our results with the findings of these 
prospective studies are limited due to differences in study 
populations (only men), sarcopenia definitions, length of fol-
low-up, cut-off values to define low baseline 25OHD levels, 
and due to diverging confounding adjustment.
A large problem of prospective studies among older 
cohorts are competing risks, with numerous losses to fol-
low-up due to death. In a previous KORA-Age analysis, 
low vitamin D status was associated with higher mortality 
[37]. Assuming that older individuals may often develop 
sarcopenia before death [38, 39], we tried to address the 
problem of competing risks by means of a combined end-
point, which included incident cases of sarcopenia and all 
losses to follow-up due to death. We found a strong positive 
association of low baseline 25OHD < 25 vs. ≥ 50 nmol/L 
with this combined outcome, highlighting the importance 
of considering competing risks such as mortality in older 
cohorts. Future longitudinal studies should include repeated 
follow-up examinations after short time periods to identify 
individuals who develop incident sarcopenia before death.
Possible Mechanisms, Including PTH
Mechanistically, a direct effect of the biologically active 
form of vitamin D on muscle has been suggested follow-
ing the localization of a vitamin D receptor expressed on 
human muscle tissue [13]. Other studies have explored the 
well-known inverse relationship between serum 25OHD and 
PTH, showing effects of increased PTH levels on skeletal 
muscle mass and function [6], and suggesting that hyperpar-
athyroidism secondary to vitamin D deficiency may mediate 
the effect of vitamin D on muscle [40].
Table 3  Prospective associations of baseline 25OHD levels with annual changes in related muscle parameters, n = 702
Statistically significant values are highlighted in bold (p < 0.05)
Results of multiple linear regression analyses expressed as β (95% CI). ß coefficient is the mean difference in percentage change per year. Model 
1 adjusted for sex and age; Model 2 fully adjusted for DAG confounders: sex, age, Nutrition Score (SCREEN II), physical activity, BMI and use 
of vitamin D supplements; Model 3 fully adjusted plus PTH tertiles; *p < 0.05 versus ref, **p < 0.01 versus ref
25OHD 25-hydroxyvitamin D categorized as deficiency (< 25 nmol/L), insufficiency (25 to  < 50 nmol/L) and sufficiency (≥ 50 nmol/L, ref), 
PTH parathyroid hormone; TUG test Timed Up and Go test, DAG, directed acyclic graph, OR odds ratio, CI confidence interval, SD standard 
deviation
Outcome at follow-
up (continuous)
25OHD % change per year 
of outcome, mean 
(± SD)
n β (95% CI)
Model 1: age and sex Model 2: fully adjusted Model 3: Model 
2 + PTH
Muscle Mass Index All − 0.17% (± 2.28) 681
Deficiency − 0.89% (± 2.98) 75 − 1.03 (− 1.61, − 0.45)** − 0.94 (− 1.55, − 0.34)** -0.92 (− 1.54, − 0.30)*
Insufficiency − 0.40% (± 2.29) 262 − 0.52 (− 0.89, − 0.15)** − 0.47 (− 0.86, − 0.09)* − 0.46 (− 0.84, − 0.07)*
Sufficiency 0.15% (± 2.04) 344 0.00 (ref) 0.00 (ref) 0.00 (ref)
Grip strength All − 0.42% (± 7.16) 702
Deficiency − 1.10% (± 7.38) 76 0.03 (− 1.79, 1.85) 0.34 (− 1.58, 2.25) 0.46 (− 1.48, 2.41)
Insufficiency − 0.12% (± 7.76) 267 0.57 (− 0.57, 1.72) 0.71 (− 0.48, 1.91) 0.72 (− 0.48, 1.93)
Sufficiency − 0.50% (± 6.64) 359 0.00 (ref) 0.00 (ref) 0.00 (ref)
Gait speed All 2.95% (± 8.12) 590
Deficiency 2.20% (± 6.75) 54 − 0.65 (− 3.07, 1.76) − 0.71 (− 3.23, 1.80) − 0.54 (− 3.08, 2.00)
Insufficiency 3.27% (± 8.77) 218 0.58 (− 0.84, 2.00) 0.64 (− 0.83, 2.11) 0.75 (− 0.73, 2.23)
Sufficiency 2.86% (± 7.86) 318 0.00 (ref) 0.00 (ref) 0.00 (ref)
Time to complete the 
TUG test
All − 0.19% (± 8.36) 612
Deficiency 3.29% (± 13.28) 58 3.47 (1.14, 5.81)** 3.06 (0.63, 5.49)* 3.06 (− 0.02, 2.85)**
Insufficiency 0.68% (± 8.05) 229 1.49 (0.11, 2.88)* 1.42 (− 0.02, 2.85) 1.53 (0.09, 2.98)*
Sufficiency − 1.42% (± 7.14) 325 0.00 (ref) 0.00 (ref) 0.00 (ref)
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In the present study, adjustment for PTH tertiles strength-
ened the association of 25OHD with sarcopenia in cross-
sectional analyses, but only slightly attenuated it in prospec-
tive analyses. This suggests that a meaningful mediating 
effect of PTH was unlikely, though the number of partici-
pants with hyperparathyroidism was very small. Of note, 
there may be other indirect biological pathways mediating 
the effect of vitamin D on muscle, including hypocalcemia 
[14] or hypophosphatemia [15]. Further mechanistic studies 
are required to better understand the mechanisms by which 
25OHD levels may influence sarcopenia and its onset.
Strengths and Limitations
Strengths include the use of a large, broadly representative, 
sample of community-dwelling German older adults with 
prospective data. Because reasons for non-participation were 
systematically recorded, we were able to incorporate with-
drawal due to death as a combined outcome with incident 
sarcopenia. We have included 25OHD levels in addition to 
a wide range of covariates trough DAG modeling, thereby 
minimizing confounding in examining the causal association 
between vitamin D status and sarcopenia. Nonetheless resid-
ual confounding cannot be entirely excluded. Furthermore, 
we could not account for the effects of change in 25OHD 
levels on change in muscle parameters, because 25OHD lev-
els were only measured at baseline. The power of the present 
study was limited especially regarding analyses on incident 
sarcopenia due to the low incidence in our rather healthy 
study population. While the EWGSOP allows use of BIA 
in conjunction with the Janssen multiple regression predic-
tion equation for estimation of the skeletal muscle mass [17], 
we recognize that this approach should be used with caution 
because estimates of skeletal muscle mass can be artificially 
Table 4  Prospective associations of baseline 25OHD levels with the incidence of sarcopenia (or death) and related muscle parameters, n = 702
Statistically significant values are highlighted in bold (p < 0.05)
Results of multiple logistic regression analyses expressed as OR (95% CI): Model 1, adjusted for sex and age; Model 2 fully-adjusted for DAG 
confounders: sex, age, Nutrition Score (SCREEN II), physical activity, BMI and use of vitamin D supplements; Model 3 fully adjusted plus PTH 
tertiles; *p < 0.05 versus ref, **p < 0.01 versus ref
25OHD 25-hydroxyvitamin D categorized as deficiency (< 25 nmol/L), insufficiency (25 to  < 50 nmol/L) and sufficiency (≥ 50 nmol/L, ref), 
PTH parathyroid hormone, TUG test Timed Up and Go test, DAG directed acyclic graph, OR odds ratio, CI confidence interval
Outcome at follow-up (dichoto-
mized)
25OHD Incidence 
of outcome 
(%)
n OR (95% CI)
Model 1: age and sex Model 2: fully adjusted Model 3: Model 2 + PTH
Sarcopenia All 4.3 702
Deficient 5.3 76 1.10 (0.29–3.44) 2.38 (0.54–8.99) 1.91 (0.43–7.24)
Insufficiency 5.2 267 1.35 (0.61–3.05) 2.10 (0.89–5.04) 1.98 (0.83–4.83)
Sufficiency 3.3 359 1.00 (ref) 1.00 (ref) 1.00 (ref)
Sarcopenia or death All 11.5 759
Deficiency 23.4 94 2.44 (1.25–4.69)** 3.19 (1.54–6.57)** 2.95 (1.40–6.18)**
Insufficiency 12.5 289 1.51 (0.89–2.57) 1.84 (1.06–3.22)* 1.77 (1.01–3.12)*
Sufficiency 7.7 376 1.00 (ref) 1.00 (ref) 1.00 (ref)
Low Muscle Mass Index All 7.8 681
Deficiency 8.0 75 0.97 (0.34–2.42) 2.52 (0.76–7.59) 2.39 (0.72–7.30)
Insufficiency 9.2 262 1.24 (0.67–2.27) 2.01 (1.02–4.01)* 1.94 (0.98–3.90)
Sufficiency 6.7 344 1.00 (ref) 1.00 (ref) 1.00 (ref)
Low grip strength All 34.2 702
Deficiency 44.7 76 1.14 (0.63–2.01) 1.07 (0.58–1.95) 0.99 (0.53–1.82)
Insufficiency 38.2 267 1.21 (0.84–1.74) 1.17 (0.80–1.71) 1.13 (0.77–1.66)
Sufficiency 29.0 359 1.00 (ref) 1.00 (ref) 1.00 (ref)
Slow gait speed All 6.8 590
Deficiency 13.0 54 2.05 (0.68–5.64) 1.67 (0.53–4.85) 1.54 (0.51–4.91)
Insufficiency 8.7 218 1.66 (0.80–3.52) 1.53 (0.71–3.40) 1.50 (0.68–3.38)
Sufficiency 4.4 318 1.00 (ref) 1.00 (ref) 1.00 (ref)
More time needed to complete the 
TUG test
All 10.3 612
Deficiency 20.7 58 2.71 (1.15–6.16) 2.02 (0.82–4.83) 1.94 (0.77–4.70)
Insufficiency 13.1 229 1.83 (1.01–3.39) 1.57 (0.82–3.02) 1.53 (0.79–2.97)
Sufficiency 6.5 325 1.00 (ref) 1.00 (ref) 1.00 (ref)
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elevated due to altered hydration, including fluid accumula-
tion and hypohydration [41]. Furthermore, PTH levels are 
subject to diurnal rhythms and influenced by the ingestion of 
calcium-containing foods, hence PTH results may have been 
affected by the non-fasting status of KORA-Age participants 
and possible batch effects associated with sampling across 
extended time periods. Accurate interpretation and compari-
son of PTH results across studies may also be hampered by 
the lack of standardization and robust reference ranges due to 
variable analytical methods used for its determination [23].
Conclusion
In conclusion, our finding suggests that a low vitamin D status 
may be an early risk factor for changes in muscle mass and 
physical performance in older adults. Replenishing 25OHD 
levels may be important for the preservation of specific sarco-
penia-related muscle parameters but further randomized trials 
are needed to assess whether the observed associations are 
causal and to determine optimal 25OHD levels for muscle 
health. We could not demonstrate a statistically significant 
association of low vitamin D status with incident sarcopenia, 
but a significant association was found with the combined 
endpoint of sarcopenia and death. This highlights the need 
for future well-designed prospective studies that address the 
issue of competing risks such as mortality in older cohorts.
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Abstract: Understanding how changes in nutritional status influence musculoskeletal recovery
after falling remains unclear. We explored associations between changes in nutritional status and
musculoskeletal health in 106 community-dwelling older adults aged  65 years, who attended the
Falls and Fractures Clinic at Sunshine Hospital in St Albans, Australia after falling. At baseline and
after 6 months, individuals were assessed for Mini Nutritional Assessment (MNA®), grip strength,
gait speed, Timed Up and Go (TUG) test, Short Physical Performance Battery (SPPB), and bone
turnover marker levels. Associations were examined using multiple linear regression, adjusted for
baseline covariates and post-fall care plans. Over 6 months, the prevalence of malnutrition or risk
thereof decreased from 29% to 15% using MNA <24/30. Specifically, 20 individuals (19%) improved,
7 (7%) deteriorated, and 73 (69%) maintained nutritional status, including 65 (61%) who remained
well-nourished and 8 (8%) who remained malnourished/at risk. A 1-point increase in MNA score
over 6 months was associated with an increase of 0.20 points (95% confidence interval 0.10, 0.31,
p < 0.001) in SPPB score. Improvement in nutritional status was associated with improvement in
physical performance, providing a basis for interventional studies to ascertain causality and evaluate
nutritional models of care for post-fall functional recovery in older adults.
Keywords: malnutrition; MNA; nutrition; physical performance; bone turnover; sarcopenia;
osteosarcopenia; falls; elderly; prospective
1. Introduction
About a third of community-dwelling older adults aged  65 years in Western countries fall
each year and the frequency of falls and fall-related injuries (fractures or head trauma) increase with
age [1]. Falls increase the risk of hospitalization and nursing home admission, as well as morbidity and
mortality [2]. Investigating modifiable risk factors of falls is a key priority area for healthcare systems,
which strive to identify conditions that prevent falls.
Poor nutritional status has been considered an important modifiable risk factor for falls [3].
Compared to well-nourished older adults, risk of experiencing falls has been shown in a meta-analysis
of prospective studies to be 45% higher in malnourished individuals or those at risk of malnutrition
(n = 9510) [4], based on the validated Mini Nutritional Assessment (MNA®) tool [5]. In an interventional
Nutrients 2019, 11, 1551; doi:10.3390/nu11071551 www.mdpi.com/journal/nutrients
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study by Swanenburg et al., the combination of a three-month calcium/vitamin D supplementation
plus protein/exercise was associated with a 89% reduction in the rate of falls over 12 months compared
to only calcium/vitamin D supplementation in older women aged  65 years with low mineral density
(n = 20) [6]. Altogether, these findings suggest that nutritional status should be properly considered
when assessing the risk of falls in community-dwelling older adults; yet it is currently not included in
most fall risk screening tools [7].
Poor nutritional status can be a consequence of underlying comorbid conditions [8], which may
increase the risk of falls due to clinical and adverse e↵ects on cognitive, functional, and physical
performance [9]. Poor nutritional status due to inadequate nutritional intake, especially of proteins,
can also be detrimental for maintaining the integrity and function of skeletal muscle and bone [10–12],
possibly increasing the risk for sarcopenia, osteoporosis or both [13–16]. Sarcopenia-associated
risk of falling and increased bone vulnerability have a synergistic impact on falls and fractures
occurrence [17,18]. The impact of nutritional status on the risk of falls can thus be explored through
the pathway of musculoskeletal health as an important contributor to falls risk [19,20].
Evidence suggests that malnutrition based on MNA is able to predict musculoskeletal decline
in various healthcare settings [21–23], but the relationship between nutritional changes and
musculoskeletal outcomes remains under-researched [24], in particular among those who fall.
Improving knowledge about how nutritional changes may influence relevant musculoskeletal outcomes
might be important to e↵ective targeting of multidisciplinary post-fall interventions for older adults
living in the community. This study aimed to investigate changes in nutritional status in older adults
with a history of falling using the validated MNA®, and to determine associations between changes
in nutritional status and relevant musculoskeletal outcomes. We hypothesized that improvement in
nutritional status is associated with greater musculoskeletal recovery.
2. Materials and Methods
2.1. Study Design and Individuals
This retrospective observational study examined associations between changes in nutritional
status and musculoskeletal outcomes among community-dwelling older adults who attended the
Falls and Fractures Clinic at the Australian Institute for Musculoskeletal Science (Western Health-
Sunshine Hospital) in St Albans, VIC, Australia. A multidisciplinary team at the clinic, including a
geriatrician, a fracture liaison nurse, an accredited exercise physiologist, and a bone densitometrist,
provides comprehensive care for older adults with a history of more than two falls in the previous
year, or a single fall with established gait and/or balance problem, and/or clinical or radiological risk of
falls and/or fractures. We analyzed information from baseline attendance between October 2016 and
December 2018 and from follow-up attendance after a median time of 6 months (interquartile range
(Q1–Q3) 6–8 months). All measurements obtained were part of standard care practices at this health
service. The Western Health Low Risk Ethics Panel approved the registration of the Falls and Fractures
Clinic Databank (DB2017.13, date of approval 23 October 2018) and the research protocol of the present
study (QA2018.90_48118, date of approval 5 December 2018). Participant consent was waived due to
use of de-identified data collected as part of standard care at the clinic and due to the low risk nature
of the study beyond the initial consent to attend the clinic.
2.2. Demographic and Clinical Measures
Demographic data was obtained from the patient medical record including age, gender,
and residential location. Comprehensive clinical assessment was performed by the geriatrician
and the nurse as part of routine care practices on clinic attendance including comorbidities, family
history, fracture history, osteoporosis risk assessment (e.g., hormone replacement therapy, menopause
age, smoking, alcohol), falls risk (e.g., hearing and visual deficit, altered elimination, impaired
mobility), assessment for postural drop, and list of current medications. For the purpose of this study,
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a Charlson age-comorbidity index (CACI) was generated, with an index of  5 being suggestive of
severe comorbidity [25]. The CACI calculation is explained in Supplementary Table S1. Polypharmacy
was defined as use of  5 prescribed or regularly taken medications, including drugs and dietary
supplements. Depression was screened using the Short Form Geriatric Depression Scale (GDS), with a
score of  6/15 points considered as “suggestive of depression” [26].
2.3. Nutritional Status
Nutritional status was evaluated by the nurse using the Mini Nutritional Assessment (MNA®),
which is a validated screening and assessment tool for older adults in community and hospital settings.
The full MNA consists of 18 items (6 questions in the screening part, also called the MNA Short-Form
(MNA-SF), and 12 questions in the assessment part) capturing anthropometric measures, dietary
intake, appetite, general health, and mobility [5]. The screening part first identifies older adults as
“well-nourished” (MNA-SF   12/14) or “at nutritional risk” (MNA-SF < 12/14), so that the full MNA
is performed only if an individual is “at nutritional risk”. The full categorized MNA then classifies
individuals into “malnourished” (MNA < 17/30), “at risk of malnutrition” (17/30  MNA < 24/30)
or “well nourished” (MNA   24/30) [5]. To calculate a full continuous MNA score, individuals with
MNA-SF   12/14 in the screening part were adjusted into a full MNA score (MNA-SF + 16 points) to
obtain a full score ranging 0–30 points. Weight and height were measured using standardized scales to
the nearest 0.1 kg and 0.01 m, respectively.
2.4. Biochemical Measures
Fasting venous blood was collected for the measurement of serum albumin, 25-hydroxyvitamin D
(25OHD), parathyroid hormone (PTH), hemoglobin, and C-terminal telopeptide of type 1 collagen (CTx).
Serum albumin, and hemoglobin levels were determined using automated standard laboratory methods.
Serum 25OHD levels were measured by chemiluminescence immunoassay on a LIAISON® XL analyzer
(DiaSorin S.p.A., Saluggia, Italy). Circulating intact PTH was measured by immunochemoluminometric
assay performed on ADVIA Centaur® (Siemens Healthcare Diagnostics, Deerfield, MA, USA). Serum
CTx levels were measured by electrochemiluminescence immunoassay on a Cobas® 6000 analyzer
(Roche Diagnostics International Ltd, Rotkreuz Switzerland). Cut-o↵ values for subnormal levels were
25OHD < 75 nmol/L [27], PTH > 6.9 pmol/L, and hemoglobin <130 g/L (men), <120 g/L (women).
Estimated-glomerular filtration rate (eGFR) was calculated from serum creatinine as an indicator of renal
function (MDRD formula [28]), with subnormal cut-o↵values of<60 mL/min/1.73 m2. All measurements
were performed at the pathology networks a liated with the Western Health-Sunshine Hospital in St.
Albans, Australia.
2.5. Post-Fall Care Plan
After review of the results of the complete assessment of the individuals’ risk of falls and fractures
by the multi-disciplinary team, individuals were provided with individualized care plans that included
pharmacological (e.g., osteoporosis treatment, vitamin D supplements, protein supplements), and
non-pharmacological recommendations (e.g., nutrition advice, physical exercise), with a focus on
preventing new or recurrent episodes of falls and/or osteoporotic fractures. The care plan was
patient-centered through consideration of the risk assessment, individual patient circumstances,
and preferences. In consultation with their local general practitioners, individuals were involved in the
management of their respective care plan. The current study looks into changes in nutritional status
and musculoskeletal components over a period of 6 months.
2.6. Musculoskeletal Outcome Measures
Musculoskeletal outcome measures were evaluated by the exercise physiologist as part of standard
patient assessment on attendance at baseline and 6-month follow-up. Grip strength (kg) was measured
with a handheld JAMAR hydraulic dynamometer (Sammons Preston Inc., Bolingbrook, IL, USA).
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Individuals had to squeeze the device as hard as possible 3 times in each hand; the highest value was
recorded. Gait speed (m/sec) was evaluated using a sensitive walkway (GAITRite system, 160 model,
CIR Systems Inc., Havertown, PA, USA), which recorded spatiotemporal gait speed over 4.8 m with
individuals walking at usual speed. The best result of two trials was considered. The Timed Up and
Go (TUG) test (sec) measured the time taken to stand up from a standard chair, walk a distance of 3 m,
turn, walk back to the chair, and sit down again [29]. The Short Physical Performance Battery (SPPB) is
a group of measures that combines the results of the gait speed, chair stand, and balance tests [30].
We included serum CTx levels (assessment described under biochemical measures) as a measure of
bone turnover.
2.7. Osteopenia/Osteoporosis and Sarcopenia
Body composition and areal bone mineral density (BMD) at three sites (lumbar spine, total hip,
and femoral neck) were assessed by the bone densitometrist using a Horizon dual energy X-ray
absorptiometry (DXA) machine (Hologic Inc., Bedford, MA, USA). DXA scans were only performed
at baseline, and osteopenia/osteoporosis was defined as a BMD T-score < 1.0 SD on at least one of
the three regions. As recommended by the Australian and New Zealand Society for Sarcopenia and
Frailty Research (ANZSSFR) [31], sarcopenia was defined according to the EWGSOP 2010 definition by
fulfillment of low height-adjusted appendicular lean mass (ALM/height2) combined with low grip
strength or slow gait speed [32]. (ALM/height2) was calculated automatically by the DXA machine.
We applied the EWGSOP cut-o↵s for low ALM/height2: 7.26 kg/m2 (⇢), 5.5 kg/m2 (⇡); for low grip
strength: <30 kg (⇢), <20 kg (⇡) and for slow gait speed: 0.8 m/sec [32]. Osteosarcopenia was defined
as the simultaneous presence of osteopenia/osteoporosis and sarcopenia.
2.8. Statistical Analysis
Statistical analysis was performed using SAS, version 9.4 (SAS Institute Inc., USA). Statistical
significance was based on a two-sided p-value <0.05. Normality was assessed using the Shapiro-Wilk
test. Mean (standard deviation (SD)) or median (25th percentile (Q1), and 75th percentile (Q3))
were reported for continuous data, and number (percentage (%)) for categorical data. Change (D) in
continuous variables was calculated as the di↵erence between follow-up and baseline, e.g., DMNA
= [MNA score (follow-up)—MNA score (baseline)]. To compare baseline and follow-up results,
di↵erences were tested using paired t-test or Wilcoxon signed-rank test for normally-distributed or not
normally-distributed paired samples, respectively.
As proof of concept, multiple linear regression analyses were first performed to test the
cross-sectional associations between baseline MNA score and baseline musculoskeletal outcomes.
Analyses were adjusted for baseline variables (age, sex, GDS, CACI, and number of medications—all
continuous except sex).
For main analysis, individuals were divided into four subgroups based on change in MNA
category from baseline to follow-up: (1) Improved nutritional status from baseline to follow-up; (2)
Deteriorated; (3) Maintained but remained malnourished or at risk of malnutrition; (4) Maintained and
remained well-nourished (reference group). Comparison of clinical, biochemical and musculoskeletal
outcome measures between the subgroups vs. the reference group was analyzed using t-test or
Wilcoxon rank-sum test for normally-distributed or not normally-distributed variables, respectively.
To explore the longitudinal associations between changes in nutritional status and musculoskeletal
outcomes, multiple linear regression analyses were performed for each of the musculoskeletal outcome.
Change in nutritional status was considered as both continuous (DMNA) and categorized exposure.
Analyses were adjusted for the baseline outcome, baseline variables (age, sex, GDS, CACI, and number
of medications—all continuous except sex), and care plan variables (osteoporosis treatment, vitamin
D supplements use, protein supplements use, and physical activity—all categorical). When change
in nutritional status was used as continuous exposure (DMNA), analyses were additionally adjusted
for baseline MNA score. To avoid deletion of information-rich participants, missing values for four
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binary variables were coded as a separate category. Scatter and residual plots were examined to
determine if DMNA was related to musculoskeletal changes in a linear manner and if the errors
components were independent, homogenous with respect to the variance, and had a mean of zero.
If these assumptions were violated, the outcome and/or independent variables were log-transformed
to ensure good model fit.
To control for multiple testing, we ranked our hypotheses. Our primary hypothesis is that
improvement in nutritional status is associated with greater musculoskeletal recovery. Our secondary
hypotheses are that individuals who deteriorated and remained malnourished or at risk of malnutrition
are associated with poorer musculoskeletal recovery. As such, p-values from multiple linear regression
analyses were interpreted in the view of multiple comparisons. If the p-value was fairly large
(0.01  p < 0.05), we did not interpret them as definitely true, but considered that they may be likely
false positive, while very small p-values (p < 0.01 and p < 0.001) were interpreted as likely real findings.
3. Results
3.1. Descriptive Characteristics, Including Change in Nutritional Status
Out of 254 patients screened at the Falls and Fractures Clinic between October 2016 and December
2018, 106 (76% female) consecutive individuals with median age of 79 (Q1, Q3 72, 82) years were
re-assessed at 6-month follow-up. Table 1 presents descriptive characteristics of this study sample. On
attendance at baseline, polypharmacy and severe comorbidity were quite prevalent (67% taking  5
medications and 45% with a CACI  5). The median number of reported falls in the past year was 2
falls. Most individuals (92%) were osteopenic/osteoporotic, and 22% were sarcopenic. On attendance
at follow-up, the median number of reported falls in the past 6 months decreased to 0 falls. Moreover,
91 (86%) individuals reported using vitamin D supplements and 5 (5%) protein supplements, 70 (66%)
reported having an osteoporosis treatment, and 51 (48%) reported being physically active, as part of
the post-fall care plans recommended.
Table 1. Descriptive characteristics of the study sample, including change in nutritional status.
Characteristic Descriptive Statistics All (n = 106)
Baseline
Age, year Median (Q1, Q3) 79 (72, 82)
Female n (%) 80 (75.5)
BMI at baseline, kg/m2 Median (Q1, Q3) 27.8 (23.8, 31.9)
Weight at baseline, kg Median (Q1, Q3) 69.6 (58.5, 85.0)
Height, m Mean (SD) 1.59 (0.09)
Current smoker g n (%) 11 (10.4)
Number of falls (past 12 months) Median (Q1, Q3) 2 (1, 2)
Number of fractures (past 5 years) Median (Q1, Q3) 1 (1, 1)
Severe comorbidity (CACI  5) n (%) 48 (45.3)
Polypharmacy ( 5 medications) n (%) 71 (67.0)
Suggestive of depression a (GDS  6/15) n (%) 26 (24.5)
Osteopenia/osteoporosis c n (%) 97 (91.5)
Sarcopenia b n (%) 22 (20.8)
Osteosarcopenia b n (%) 22 (20.8)
Nutritional status
MNA at baseline, score Median (Q1, Q3) 29 (23, 30)
Malnourished or at risk at baseline (MNA <24/30) n (%) 31 (29.3)
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Table 1. Cont.
Characteristic Descriptive Statistics All (n = 106)
Follow-up
DBMI h, kg/m2 Median (Q1, Q3) 0.6 ( 0.2, 1.5) *
Dweight f, kg Median (Q1, Q3) 0.6 ( 1.0, 3.0) *
Number of falls d (past 6 months) Median (Q1, Q3) 0 (0, 1)
Number of fractures d (past 6 months) Median (Q1, Q3) 0 (0, 0)
Osteoporosis treatment e n (%) 70 (66.0)
Vitamin D supplement use e n (%) 91 (85.9)
Protein supplement use e n (%) 5 (4.7)
Physically active j n (%) 51 (48.1)
Nutritional status
DMNA d, score Median (Q1, Q3) 0 (0, 3.3) *
Malnourished or at risk at follow-up d (MNA <24/30) n (%) 16 (15.1)
Q1, Q3 = 25th, 75th percentile; CACI = Charlson age-comorbidity index; GDS = Geriatric Depression Scale; MNA=
Mini Nutritional Assessment; BMI = body mass index; number of missing values: a 1, b 3, c 5, d 6, e 10, f 14 g
15, h 16, j 27; *: p < 0.05 for paired t-test or Wilcoxon signed-rank test for the di↵erence between baseline and
follow-up values.
The prevalence of malnutrition or risk of malnutrition based on an MNA score <24/30 was 29% at
baseline and 15% at 6-month follow-up. Most individuals maintained or improved nutritional status
with at least 75% not having a decrease in MNA score (median change of 0.0 (0.0, 3.3) points, p = 0.001)
(Table 1). Specifically, 73 individuals (69%) maintained nutritional status, including 65 (61%) who
remained well-nourished and 8 (8%) who remained malnourished or at risk of malnutrition. Moreover,
20 individuals (19%) improved and 6 individuals (7%) deteriorated nutritional status, as illustrated in
Figure 1.
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3.2. Nutritional Status and Musculoskeletal Health at Baseline
In age-sex adjusted analyses, a 1-point increase in baseline MNA score was associated with an
increase of 0.02 m/sec (95% CI 0.00, 0.03, p = 0.022) in gait speed and of 0.14 points (95% CI 0.05, 0.23,
p = 0.003) in SPPB score. Additional adjustment for baseline variables weakened the associations,
which became non-significant (Supplementary Table S2).
3.3. Changes in Nutritional Status and Musculoskeletal Health
Table 2 compares clinical, biochemical and musculoskeletal measures between subgroups of
nutritional status change using the maintained (well-nourished) nutritional status group as reference
group. The reference group was associated with significant increase in BMI (p = 0.002), weight
(p = 0.031), 25OHD levels (p = 0.013), gait speed (p < 0.001), SPPB score (p = 0.008) and decrease in CTx
levels (p < 0.001). Individuals who improved nutritional status were associated with greater increase in
BMI (p = 0.002) and weight (p = 0.006) compared to the reference group, and similar increase in SPPB
score (p = 0.177). They were not associated with significant improvement in gait speed (p = 0.193), but
their TUG time significantly decreased (p = 0.001). Those who maintained (malnourished/at risk) or
deteriorated nutritional status were not linked to significant improvement in any of the variables.
In multiple linear regression analyses (Table 3), change in nutritional status over 6 months showed
the strongest associations with SPPB. After adjusting for baseline and care plan covariates, a 1-point
increase in MNA score over 6 months was associated with an increase of 0.20 points (95% CI 0.10, 0.31,
p < 0.001) in SPPB score. In subgroup analyses, individuals who improved nutritional status had for
3.30 sec (95% CI  6.34,  0.26, p = 0.033) a larger decrease in time for the TUG test compared to the
reference group. Conversely, those who deteriorated in nutritional status had a larger decrease in SPPB
score by 1.74 points (95% CI  3.29,  0.20, p = 0.028).
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4. Discussion
Poor nutritional status is subject to intense discussion in geriatric research mainly due to its high
prevalence in older adults with falls, associations with higher morbidity and mortality risk, and e↵ects
on increased healthcare spending [33]. We assessed change in nutritional status in older adults with a
history of falling and how it is related to relevant musculoskeletal changes during post-fall recovery. We
found that improvement in nutritional status, based on increase in the MNA score over 6 months, was
associated with improvement in physical performance, based on increase in the SPPB score over time.
4.1. Changes in Nutritional Status
Approximately one-third (29%) of the studied 106 older adults were malnourished or at risk of
malnutrition at baseline. This prevalence is comparable to other studies of community-dwelling older
adults using the MNA® (6%–32%) [34]. The prevalence of malnutrition or risk thereof decreased to
15% at follow-up. Comparable observational studies in community-dwelling older adults are lacking,
but studies within inpatient settings reported a similar reduction in malnutrition prevalence (10%–13%)
based on MNA category change between admission and discharge. However, older adults receiving
inpatient services di↵er significantly in nutritional status and health recovery goals post-discharge
to the community, so that results cannot be compared to community-dwelling older adults with
confidence [24,35,36].
Most individuals (89%) maintained or improved nutritional status. It is worth noting that 8%
of them remained malnourished or at risk of malnutrition at follow-up. A smaller number (7%)
deteriorated to an extent su cient to downgrade MNA category. This implies that while improvement
or stabilization of nutritional status is possible during post-fall recovery, a number of individuals
may not reach a well-nourished state, despite provision of individualized care plans, which included
education and prescription of protein supplements, when indicated. This may have long-term
implications for musculoskeletal recovery and quality of life and highlights the need for adequate
follow-up of nutritional assessment. Moreover, while it is possible that subtle improvement or
deterioration occurred within the stable group, the degree of change may not have been su cient to
alter MNA category.
Our study further demonstrated that MNA change was consistent with significant anthropometric
(weight and BMI) changes. This is an important finding, as it is valuable to have a validated nutrition
assessment tool to monitor nutrition progress over time, rather than relying only on anthropometric
or biochemistry measures such as albumin, which may be confounded by clinical factors such as
inflammation [37,38].
4.2. Changes in Nutritional Status and Musculoskeletal Health
Over 6 months, there were significant improvements in physical performance (based on gait
speed, SPPB score, and TUG test performance) and in CTx levels. For gait speed and SPPB score,
improvements were within a range indicating clinically meaningful changes [39], supporting that
performance measures may o↵er a powerful mechanism to act on healthcare needs of older adults at
risk for falls.
The observational design of this study prevents us from attributing changes of nutritional
status and musculoskeletal outcomes to specific post-fall recommendations or other causes. Care
plans were individualized through consideration of patient circumstances and treatment preferences.
Incorporation of patients’ decisions about treatment choices and their active involvement in managing
their own care plan forms an integrative part of patient-centered medicine [40].
Our research investigated whether changes in nutritional status were reflected by changes in
relevant musculoskeletal outcomes post-fall recovery. Improvement in nutritional status, based on a
1-point increase in MNA score over 6 months, was strongly associated with improvement in physical
performance, based on an increase of 0.20 points (95% CI 0.10, 0.31, p < 0.001) in SPPB score over
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time. In subgroup analyses, the improved group was significantly associated with decrease in time to
perform the TUG test and the deteriorated group with decrease in the SPPB score over time, compared
to the reference group. These tools are interrelated and provide valid and reliable measurements of
physical performance in community-dwelling older adults, incorporating elements of mobility and
balance, with the addition of strength in both the SPPB and TUG test [41]. Nevertheless, caution is
warranted when interpreting findings from subgroup analyses, because p-values were fairly large
(0.01  p < 0.05).
The impact of change in nutritional status on physical performance may be explained by direct or
indirect mechanisms. First, increased adequacy of nutritional intake (in terms of quantity and quality)
may contribute to recovery of muscle mass and function [42]. This a↵ects physical performance,
leading to functional and mobility improvements [10,11]. Improved nutritional status may also be an
indicator of decreased comorbidity, which has positive e↵ects on cognitive, functional, and physical
performance [8]. Detailed data on changes in disease-related and medical factors could not be
considered in this study and may have influenced changes between nutritional status groups and the
time taken to recover musculoskeletal health. Finally, there was no association between changes in
nutritional status and CTx levels. Physical performance may be more likely than bone turnover to
improve alongside nutritional status due to recovery of muscle mass and function.
Our findings support the hypothesis that adequate nutritional follow-up support might increase
relevant functional abilities during recovery from a fall. Two recent intervention studies, involving
over 200 older adults aged  65 years each, showed that nutrition interventions (including enriched
diets and/or oral nutritional supplements, home visits and/or telephone follow-ups) yielded significant
improvements in weight and functional status over 3 months [43]. Another randomized control study
involving over 150 geriatric patients aged >65 years at nutritional risk demonstrated the positive e↵ect
of individualized dietician counseling at home after discharge from hospital [44]. Perhaps this study
design [44] can be used to conduct larger randomized controlled trials evaluating the e↵ectiveness
of specific nutritional interventions and models of care to improve nutritional and musculoskeletal
measures in older adults at risk for falls.
4.3. Strengths and Limitations
Strengths of the study include the use of validated nutritional and musculoskeletal assessment
tools, and the repeated measurements at two time points. The follow-up period of 6 months makes the
study appropriate for documenting changes in nutritional status and musculoskeletal outcomes. There
are also a number of limitations. The MNA lacks sensitivity to detect subtle changes in nutritional
status [36]. As a result, the four nutritional status change subgroups are not evenly represented and
are dominated by those who maintained well-nourished nutritional status. Another limitation arises
from the selection bias associated with the follow-up design of this study, whereby only those willing
to attend a follow-up session were assessed.
A control group was not feasible as routine geriatric care needed to be provided, which included
individualized care plans for all patients. This limits the ability to attribute changes observed in
musculoskeletal outcomes to specific recommendations. Importantly, it remains unclear whether
change in nutritional status has a causal role in change in physical performance, or whether it is a case
of reverse causation. The possibility of the temporal association between nutritional status and physical
performance being due to residual confounding by unmeasured genetic, lifestyle or environmental
factors cannot be ruled out. Finally, our findings may not be generalized because of the heterogeneous
and convenience nature of the database.
5. Conclusions
Approximately one third of community-dwelling older adults with a history of falling were
malnourished or at risk of malnutrition at baseline, and nearly one fifth improved nutritional status at
6-month follow-up. Improvement in nutritional status, based on increase in the MNA score over 6
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months, was associated with improvement in physical performance, based on increase in the SPPB
score over time. Larger intervention studies are required to ascertain causality and to evaluate specific
nutritional interventions and models of care to improve nutritional status and functional recovery in
older adults at risk for falls.
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